

# Cigna Medical Coverage Policy- Therapy Services Electric Stimulation for Pain, Swelling and Function in a Clinic Setting

Effective Date: 11/15/2023  
Next Review Date: 11/15/2024



---

## INSTRUCTIONS FOR USE

*Cigna / ASH Medical Coverage Policies are intended to provide guidance in interpreting certain standard benefit plans administered by Cigna Companies. Please note, the terms of a customer's particular benefit plan document may differ significantly from the standard benefit plans upon which these Cigna / ASH Medical Coverage Policies are based. In the event of a conflict, a customer's benefit plan document always supersedes the information in the Cigna / ASH Medical Coverage Policy. In the absence of a controlling federal or state coverage mandate, benefits are ultimately determined by the terms of the applicable benefit plan document. Determinations in each specific instance may require consideration of:*

- 1) the terms of the applicable benefit plan document in effect on the date of service*
- 2) any applicable laws/regulations*
- 3) any relevant collateral source materials including Cigna-ASH Medical Coverage Policies and*
- 4) the specific facts of the particular situation*

*Where coverage for care or services does not depend on specific circumstances, reimbursement will only be provided if a requested service(s) is submitted in accordance with the relevant guidelines and criteria outlined in this policy, including covered diagnosis and/or procedure code(s) outlined in the Coding Information section of this policy. Reimbursement is not allowed for services when billed for conditions or diagnoses that are not covered under this policy. When billing, providers must use the most appropriate codes as of the effective date of the submission. Claims submitted for services that are not accompanied by covered code(s) under this policy will be denied as not covered.*

*Cigna / ASH Medical Coverage Policies relate exclusively to the administration of health benefit plans.*

*Cigna / ASH Medical Coverage Policies are not recommendations for treatment and should never be used as treatment guidelines.*

*Some information in these Coverage Policies may not apply to all benefit plans administered by Cigna. Certain Cigna Companies and/or lines of business only provide utilization review services to clients and do not make benefit determinations. References to standard benefit plan language and benefit determinations do not apply to those clients.*

---

## **Medically Necessary**

**Use of electric stimulation (e.g. TENS, EMS) is considered medically necessary in a clinic setting and under the direct supervision of a physical therapist or similar professional when prescribed as part of a comprehensive treatment program for pain and swelling, and only used short term up to 2 weeks.**

**Note: The medical records must document a response to the use of electrical stimulation, including specific parameters related to the type of electric stimulation (e.g. low or high frequency TENS, electrode placement).**

Electric Stimulation for Pain, Swelling and Function in a Clinical Setting (CPG 272)

**Neuromuscular Electrical Stimulation (NMES) is considered medically necessary for disuse atrophy where the nerve to the muscle is intact and the individual has any of the following non-neurological reasons for the disuse atrophy and only in conjunction with active exercise:**

- Major hip or knee surgery where there is failure to respond to basic therapeutic exercises as initiated in physical therapy/rehabilitation; or
- Previous immobilization (e.g. casting or splinting) of an extremity (arm or leg)

**Experimental, Investigational, Unproven**

**Each of the following electrical stimulation devices, therapies, and treatments is considered experimental, investigational, or unproven for the treatment of any condition:**

- Cranial electrotherapy stimulation
- Deep Pharyngeal Neuromuscular Stimulation (DPNS)
- Hako-Med treatments
- H-WAVE® stimulation
- Microcurrent electrical nerve stimulation (MENS) therapy
- Microcurrent point stimulation
- Neufit Neubie device
- NMES/Electrical Stimulation (e.g. Guardian dysphagia dual chamber unit, VitalStim Therapy device)
- Pelvic floor stimulation (electric and magnetic stimulation)
- Percutaneous Electrical Nerve Stimulation (PENS) and Percutaneous Neuromodulation Therapy (PNT)
- RST-SANEXAS neoGEN® Electric cell-Signaling Treatments (EcST)
- Transcutaneous electrical modulation pain reprocessing (TEMPR) (e.g., Scrambler therapy, Calmare®)
- Threshold Electrical Stimulation

**Electrical stimulation (except NMES) is contraindicated in areas of sensory deficits. A patient's sensory deficits (decrease or loss) do not allow them to provide the correct feedback necessary for the safe and effective application to the affected area. Electrical stimulation in other related areas without sensory deficits may be appropriate.**

**Note: For information on home electrical stimulation devices (electrical stimulators) please refer to Cigna Coverage Policy Electrical Stimulation Therapy and Home Devices.**

---

**DESCRIPTION**

Electrical stimulation (ES) therapy involves the application of electrodes to the affected area of the body for the purpose of delivering electrical current. There are several forms of electrical current used in rehabilitation settings. Electrical stimulation is used for muscle re-education (disuse atrophy), pain relief, reduction of swelling, and healing enhancement. This CPG will focus on the use of electric stimulation for pain, swelling and function (muscle re-education/disuse atrophy) when used in the outpatient clinic setting.

**GENERAL BACKGROUND**

A TENS unit must be distinguished from other electrical stimulators (e.g., neuromuscular stimulators) which are used to directly stimulate muscles and/or motor nerves. Transcutaneous electrical nerve stimulation (TENS) is characterized by biphasic current and selectable parameters such as pulse rate and pulse width. TENS uses a battery-operated device that applies electrical stimulation via transmission of pulses of various configurations at the site of pain by wired electrodes that are taped to the surface of the skin. For example, conventional TENS or

high frequency TENS delivers 40–150 hertz (Hz) compared to acupuncture-like TENS that delivers a low frequency at 1–10 Hz. Pulsed TENS uses low-intensity firing in high-frequency bursts at 100 HZ. Units often have preset programs with variations and modulations of frequencies and durations of pulses. TENS has been used for a number of applications. In theory, TENS stimulates sensory nerves to block pain signals; it also stimulates endorphin production to help normalize sympathetic function. TENS has been used to relieve acute or chronic pain related to musculoskeletal conditions, pain associated with active or post-trauma injury, obstetrical pain, or postoperative pain. TENS for pain control occurs via the gate theory or the endogenous opiate theory. Conventional transcutaneous electrical stimulation (TENS) is an example of the use of the gate theory to control or block pain. Low rate TENS is an example of the use of the endogenous opiate theory of pain control. TENS can also be delivered through the use of a form-fitting conductive garment (for example, a garment with conductive fibers that are separated from the individual's skin by layers of fabric). This garment is applied when a condition exists that precludes conventional TENS electrode placement.

Microcurrent Electrical Nerve Stimulation (MENS) involves the use of a device that delivers small amounts of electrical current (millionths of an amp) to help relieve pain and heal soft tissues of the body. The application of microcurrent stimulation to an injured area is proposed to realign the body's electrical current and increase the production of adenosine triphosphate, resulting in increased healing and recovery and blocking of perceived pain. The electrical current is subsensory and usually not felt. MENS differs from TENS in that it uses a significantly reduced electrical stimulation (i.e., 1,000 times less current than TENS). The goal of TENS is to block pain, while MENS acts on naturally-occurring electrical impulses to decrease pain by stimulating the healing process (Frequency Specific Microcurrent, 2014). Frequency specific microcurrent (FSM) is a type of microcurrent therapy. The microcurrent device has two separate channels that allow both the frequency and current to be set independently for each channel. FSM is proposed as a treatment option for nerve and muscle pain, shingles, and herpes (Frequency Specific Microcurrent, 2011).

The H-WAVE® electrical stimulation device generates a biphasic, exponentially decaying waveform with pulse-wide widths. Its waveform distinguishes it from TENS and other forms of electrical stimulators. H-WAVE® is classified as a powered muscle stimulator. The hypothesis that the H-WAVE® device (Electronic Waveform Lab, Inc., Huntington Beach, CA), a small-diameter fiber stimulator, is a paradigm shift of electrotherapeutic treatment of pain associated with human neuropathies and sports injuries is based on a number of its properties. The primary effect of H-WAVE® device stimulation (HWDS) is the stimulation of "red-slow-twitch" skeletal muscle fibers. The authors propose, based on the unique waveform, that the H-WAVE® device specifically and directly stimulates the small smooth muscle fibers within the lymphatic vessels ultimately leading to fluid shifts and reduced edema. The H-WAVE® device was designed to stimulate an ultra-low frequency (1-2 Hz), low tension, non-tetanzing, and non-fatiguing contraction, which closely mimics voluntary or natural muscle contractions. The H-WAVE® device can stimulate small fibers due in part to its exponentially decaying waveform and constant current generator activity. The main advantage of these technologies over currently applied electrical stimulators (e.g., TENS, interferential, NMES high-volt galvanic, etc.) is that H-WAVE® small fiber contraction does not trigger an activation of the motor nerves of the large white muscle fibers or the sensory delta and C pain nerve fibers, thus eliminating the negative and painful effects of tetanzing fatigue, which reduces transcapillary fluid shifts. Another proposed function of the H-WAVE® device is an anesthetic effect on pain conditions, unlike a TENS unit which in the short term activates a hypersensory overload effect (gate theory) to stop pain signals from reaching the thalamic region of the brain. When the H-WAVE® device is used at high frequency (60 Hz), it supposedly acts intrinsically on the nerve to deactivate the sodium pump within the nerve fiber, leading to a long-lasting anesthetic/analgesic effect due to an accumulative postsynaptic depression. The large pulse width theoretically enables contraction in the muscle for extended periods of time at a low fatigue rate and increases circulation, muscle relaxation, pain relief and wound healing. H-WAVE® stimulation has been used in the treatment of pain related to a variety of etiologies, such as diabetic neuropathy, muscle sprains, temporomandibular joint dysfunctions, or reflex sympathetic dystrophy. H-WAVE® electrical stimulation must be distinguished from the H-waves that are a component of electromyography.

Other waveforms are used for pain modulation as well, including interferential current (IFC), which is produced by two interfering alternating currents. Interferential stimulation (IFS) is characterized by 2 alternating-current sine waves of differing medium frequencies that combine together to produce an interferential current that is also known as a beat pulse or alternating modulation frequency. One of the 2 currents is held at 4,000 Hz, and the other can be held constant or varied over a range of 4,001 to 4,100 Hz. Interferential therapy (IFT) delivers a crisscross current at 4000–4150 pulses per second, resulting in deeper muscle penetration. It is theorized that

IFT prompts the body to secrete endorphins and other natural painkillers and stimulates parasympathetic nerve fibers to increase blood flow and reduce edema. Interferential currents reportedly can stimulate sensory, motor, and pain fibers. Because of the frequency, the interferential wave meets low impedance when crossing the skin to enter the underlying tissue. This deep tissue penetration can be adjusted to stimulate parasympathetic nerve fibers for increased blood flow. According to proponents, interferential stimulation differs from TENS because it allows a deeper penetration of the tissue with more comfort (compliance) and increased circulation.

High Voltage Galvanic Stimulation (HVGS) or high volt pulsed current (HVPC) is characterized by high voltage pulsed stimulation and is proposed primarily for local edema reduction through muscle pumping and polarity effect. High volt pulsed current (HVPC) is used for tissue healing and edema control based on polarity principles. Edema is comprised of negatively charged plasma proteins, which leak into the interstitial space. The theory of HVPC is that the high voltage stimulus applies an electrical potential which disperses the negatively charged proteins away from the edematous site, thereby helping to reduce edema (Cameron, 2017).

Neuromuscular electric stimulation (NMES) is the application of electrical current through electrodes on the skin to targeted muscles to elicit muscle contraction. NMES is proposed to promote neuromuscular re-education, improve motor unit recruitment, and thus to prevent or diminish muscle atrophy and is an established treatment modality for disuse atrophy when the nerve supply to the muscle is intact. NMES is typically used as a component of a comprehensive rehabilitation program. Compared to TENS, NMES delivers a stronger current with a wider pulse width. Neuromuscular electrical stimulation can be grouped into 2 categories: (i) stimulation of muscles to treat muscle atrophy due to disuse (e.g. post-surgical, immobilization), and (ii) enhancement of functional activity in neurologically impaired individuals. These devices within the second category use electrical impulses to activate paralyzed or weak muscles in precise sequence and have been utilized to provide SCI patients with the ability to walk (e.g., The Parastep I System). Neuromuscular electrical stimulation used in this manner is commonly known as functional electrical stimulation (FES).

Electric stimulated muscle contraction/neuromuscular electric stimulation (NMES) has been found to enhance muscle function gains post-surgically. Patients who have received an anterior cruciate ligament (ACL) reconstruction have demonstrated accelerated recovery and greater muscle function when NMES is used in combination with exercise; however the impact on functional outcomes is inconsistent (Cameron, 2017). Similar results were noted with knee OA patients and for other inflammatory conditions of the knee. Most research studied the use of NMES on the quadriceps muscle, however clinically NMES may be used for other joints and muscle groups (Cameron, 2017). Functional electric stimulation (FES) is proposed for use in certain neurologic populations. As an example, FES can be applied to the anterior tibialis muscle to assist in dorsiflexion during gait for patients with foot drop. Several studies support the integration of FES for patients with spinal cord injury or who have sustained a stroke for various activities. As long as the peripheral nervous system is intact, any patients with central nervous system dysfunction may benefit from FES use. In these situations, effectiveness of FES is thought to be most likely due to the direct effect of muscle strengthening in addition to increased excitability of the motor neuron pool produced by the motor level electrical stimulation (Cameron, 2017).

PENS and PNT combine the theories of electroacupuncture and TENS and the terms are often used interchangeably. PENS involves the delivery of an electrical current through the insertion of a needle below the skin at the site of pain compared to acupuncture that places needles based on energy flow. It is not the same as acupuncture. PENS is similar to TENS except that the needles are inserted one to four centimeters around or adjacent to the applicable nerve. Up to ten needs with five electrical channels may be used. PENS is generally reserved for patients who fail to obtain pain relief from TENS. PENS may also involve the application of electric stimulation to needles placed at the dermatomal levels corresponding to the painful area. PNT is a variation of PENS which was developed as a treatment for neck and back pain. This treatment involves insertion of very fine needle-like electrodes into the skin of the neck or back to stimulate nerve fibers in the deep tissues. The treatment regimen suggested by manufacturers typically consists of two to three, 30-minute sessions per week, for two to six weeks.

VitalStim® Therapy is a type of NMES that uses a mild electrical current that is intended to treat dysphagia by re-educating the muscles and improving swallowing. Guardian dysphagia dual chamber unit is proposed for use for muscle re-education by application of external stimulation for pharyngeal contraction. VitalStim® therapy was approved by the US Food and Drug Administration in 2001 for the treatment of dysphagia through the application of neuromuscular electrical stimulation to cervical swallowing muscles. To date, however, aside from

the developer's own studies, there are no peer-reviewed publications supporting these claims. Deep pharyngeal neuromuscular stimulation (DPNS) is an electrical stimulation therapy for people with dysphagia. DPNS stimulates the cranial nerves by directly touching specific areas within the mouth and throat. This causes the pharyngeal and lingual muscles to contract. Over time, this is postulated to strengthen the patient's gag reflex and help to improve long-term swallowing functionality.

Transcutaneous electrical modulation pain reprocessing (TEMPR), also called Scrambler therapy or Calmare® pain therapy, delivers electrical stimulation via the nerve fibers to convey a message of normality to the central nervous system (CNS) by a procedure defined as "scrambling" or "tricking" of information. The device is proposed to send a very low current of electrical stimulation through the nerve fibers, which carries a "no pain" signal to the brain that overrides the previous pain signal. Unlike conventional TENS, the procedure is administered in an outpatient setting and is not intended for home use. Up to five pairs of electrodes are placed on the patient's skin in the dermatome areas of pain above and below the dermatome. Amperage ranges from 3.5 to 5.0 milliamperes with a voltage range of 6.5 to 12.5 volts. Electrical stimulation is increased to the maximum tolerated intensity until pain is relieved. The device is proposed to simultaneously stimulate multiple pain areas in a patient. TEMPR has been proposed for the treatment of chemotherapy-induced peripheral neuropathy, intractable cancer pain, failed back surgery syndrome, phantom limb pain, sciatica, post-surgical pain, neuropathic pain, brachial plexus pain, low back pain, neck pain, reflex sympathetic dystrophy and post-herpetic neuralgia (PHN). Recommended treatment regimen for neuropathic pain is 10–12 daily sessions (30–45 minute) and 10–12 treatments for oncologic patients based on the patient's pain control needs (Competitive Technologies, 2020; Marineo, et al., 2012).

## **LITERATURE REVIEW**

### **TENS**

There are many published reports regarding the use of TENS for various types of conditions such as low back pain (LBP), myofascial and arthritic pain, sympathetically mediated pain, neurogenic pain, visceral pain, diabetic neuropathy and postsurgical pain. While randomized controlled trials (RCTs) have focused on both high and low frequency TENS, all of the currently available studies have methodological flaws that limit interpretation, including inadequate blinding, lack of reporting of drop outs, lack of reporting of stimulation variables, and lack of proper outcome measures (Johnson et al., 2015). However, it is recognized that TENS is widely accepted in the physician and therapy community as a treatment of a variety of etiologies of pain in combination with comprehensive treatment program.

According to the Philadelphia Panel Evidence-Based Clinical Practice Guidelines on Selected Rehabilitation Interventions for Low Back Pain publication (2001), TENS demonstrated no effectiveness for improvements in pain or function in subjects with chronic low back pain (LBP). Evidence was stated as good (level I). The Panel recommends that there is poor evidence to include or exclude TENS alone as an intervention for chronic LBP. According to The Cochrane Collaboration systematic review on TENS for chronic LBP (Khadiolkar et al., 2005) there is limited and inconsistent evidence to support the use of TENS as an isolated intervention for chronic LBP. In 2010, the Therapeutic and Technology Assessment Subcommittee of the American Academy of Neurology (AAN) published a report finding TENS ineffective for chronic low back pain (Dubinsky and Miyasaki, 2010). The results indicated that there are conflicting reports of TENS compared to sham TENS in the treatment of chronic low back pain, with two Class II studies showing benefit, but two Class I studies and another Class II study not showing benefit. Because the Class I studies are stronger evidence, TENS is established as ineffective for the treatment of chronic low back pain. Their recommendations were that TENS is not recommended for the treatment of chronic low back pain (Level A) and further research into the mechanism of action of TENS is needed, as well as more rigorous studies for determination of effectiveness. Per ACOEM guidelines, TENS for acute or sub-acute LBP or acute radicular pain syndromes is not recommended given insufficient evidence (ACOEM, 2007). In a review by Poitras and Brosseau (2008), it was determined that globally, high- and low-frequency TENS appears to have an immediate impact on pain levels in subjects with non-specific chronic LBP, with high-frequency TENS achieving better results. Studies included were of relatively poor quality and the lack of consistent parameters from study to study makes comparisons difficult. Based on this review, TENS appears to be of no benefit for long term pain or perceived disability (Poitras and Brosseau, 2008). Khadiolkar et al. (2008) updated the 2005 Cochrane Review to determine whether TENS is more effective than placebo for the management of chronic LBP. Only randomized controlled clinical trials (RCTs) comparing TENS to placebo in patients with chronic LBP were included. Four high-quality RCTs (585 patients) met the selection criteria. Clinical heterogeneity prevented the use of meta-analysis. There was conflicting evidence

about whether TENS was beneficial in reducing back pain intensity and consistent evidence in two trials (410 patients) that it did not improve back-specific functional status. There was moderate evidence that work status and the use of medical services did not change with treatment. In general, patients treated with acupuncture-like TENS responded similarly to those treated with conventional TENS. However, in two of the trials, inadequate stimulation intensity was used for acupuncture-like TENS, given that muscle twitching was not induced. Adverse effects included minor skin irritation at the site of electrode placement. Authors concluded that the evidence from the small number of placebo-controlled trials does not support the use of TENS in the routine management of chronic LBP. Further research was encouraged.

The American Society of Anesthesiologists (ASA) and American Society of Regional Anesthesia and Pain Medicine (ASRA) support the use of TENS in their revised guideline recommending that "TENS should be used as a multimodal approach to pain management for patients with chronic back pain and may be used for other pain conditions (e.g. neck and phantom limb pain)" (ASA/ASRA, 2010). A Cochrane review that identified 25 eligible RCTs was not favorable in their analysis of the literature support of TENS for various chronic pain conditions, primarily due to the quality of the available literature (Nnoaham and Kumbang, 2008). These authors found positive results for pain relief in 13 out of 22 studies that compared TENS to a placebo or other inactive control group. In studies that compared different TENS modes, seven of nine studies found no difference in pain relief between high vs. low frequency TENS. Overall, the low methodological quality and low power of the available literature did not allow the authors to make firm conclusions regarding the effectiveness of TENS for chronic pain.

In 2013, Pivec et al. studied the clinical and economic impact of TENS in patients with chronic LBP through analysis of a national database. This study evaluated patients who were given TENS compared with a matched group without TENS prior to intervention and at one-year follow-up. Patients who were treated with TENS had significantly fewer hospital and clinic visits, used less diagnostic imaging, had fewer physical therapy visits, and required less back surgery than patients receiving other treatment modalities. Jaurequi et al. (2016) conducted a systematic review and meta-analysis of the efficacy of TENS for the treatment of chronic, musculoskeletal low back pain. Thirteen studies, which included randomized controlled trials, cohort studies, and randomized crossover studies (n=267), met inclusion criteria. Follow-ups ranged from 2–24 weeks with a mean follow-up of seven weeks. The duration of treatment ranged from 2–24 weeks (mean 6 weeks). The overall standardized mean difference in pain from pre- to post-treatment with TENS showed a significant improvement of TENS on pain reduction. When subdivided into treatment duration, patients that were treated for less than five weeks (n=8 studies) had significant effects on pain, while those treated for more than five weeks did not. The heterogeneity among studies was substantially significant among the TENS groups. Limitations of the studies included: small patient populations; variations in treatment times, TENS frequency and length of follow-up; and conflicting outcomes. The authors noted that despite the positive results, large multi-center prospective randomized trials are needed to develop the appropriate treatment protocols for this patient population. According to the AHRQ Comparative Effectiveness publication on Non-Invasive Treatments for Low Back Pain (2016), additional evidence demonstrates that TENS is not effective versus sham TENS. Effectiveness of TENS was previously classified as insufficient and the strength of evidence remains low because of methodological limitations in the trials and imprecision. Evidence on harms associated with TENS was limited, but suggests an increased risk of skin site irritation without an increased risk of serious adverse events (AHRQ, 2016). According to the American College of Physician's Noninvasive Treatments for Acute, Subacute, and Chronic Low Back Pain clinical practice guideline (2017), evidence was insufficient to determine the effectiveness of transcutaneous electrical nerve stimulation (TENS).

Two practice guidelines support the use of TENS, one for rheumatoid arthritis based on positive results in one (1) RCT (Ottawa Panel Evidence-Based Clinical Practice Guidelines, 2004), and one for the treatment of knee osteoarthritis based on meta-analysis of five (5) RCTs included in the analysis (Philadelphia Panel Practice Guidelines, 2001). Johnson et al. (2015) assessed the analgesic effectiveness of TENS, as a sole treatment, for acute pain in adults. Only RCTs of adults with acute pain (< 12 weeks) were examined with TENS given as a sole treatment and assessed pain was with subjective pain scales. The types of acute pain included in this Cochrane Review were procedural pain, e.g. cervical laser treatment, venipuncture, screening flexible sigmoidoscopy and non-procedural pain, e.g. postpartum uterine contractions and rib fractures. There was a high risk of bias associated with inadequate sample sizes in treatment arms and unsuccessful blinding of treatment interventions. Seven trials reported minor adverse effects, such as mild erythema and itching underneath the electrodes and participants disliking TENS sensation. Authors concluded that this review offers

tentative evidence that TENS reduces pain intensity over and above that seen with placebo (no current) TENS when administered as a stand-alone treatment for acute pain in adults. The high risk of bias associated with inadequate sample sizes in treatment arms and unsuccessful blinding of treatment interventions makes definitive conclusions impossible.

Jin et al. (2010) conducted a systematic review to evaluate the effectiveness of TENS on diabetic peripheral neuropathy. Three randomized controlled trials (n=78) met inclusion criteria. TENS was reported more effective than placebo in the reduction of mean pain score at four and six weeks follow-up but not at 12 weeks. Pieber et al. (2010) conducted a systematic review of the literature to evaluate electrotherapy, including TENS, for the treatment of peripheral neuropathy in patients with diabetes. Three randomized controlled trials (n=76) and one retrospective review (n=54) evaluating TENS met inclusion criteria. The studies included short-term follow-ups and conflicting results. One study reported significant improvement in pain and another study reporting recurrence of pain after cessation of TENS. Due to the small patient populations, short-term treatment duration, short-term follow-up and poor study methodology, large multi-center randomized controlled trials are needed to further evaluate the long-term effect of TENS on diabetic neuropathy. Hurlow et al. (2012) conducted an update review of the 2009 review by Robb et al. One new study met inclusion criteria (n=24). There were significant differences in participants, treatments, procedures and symptom measurement tools used in the studies. The clinical utility of TENS for the treatment of cancer pain has not been established. Robb et al. (2009) conducted a systematic review of the literature to evaluate TENS for the treatment of cancer-related pain. Two randomized controlled trials (n=64) met inclusion criteria. Meta-analysis was not conducted due to the disparities between patient population, mode of TENS, treatment duration, and outcome measures prevented meta-analysis. There is insufficient evidence to support TENS for the treatment of cancer-related pain.

Mulvey et al. (2010) conducted a systematic review of randomized controlled trials to assess the effectiveness of TENS for the treatment of phantom pain and stump pain following amputation in adults. No studies were identified. Johnson et al. (2015b) conducted an update of this Cochrane review and found no new randomized controlled trials evaluating TENS for the treatment of phantom pain and stump pain. Rheumatoid Arthritis: In a systematic review of the literature, Brosseau et al. (2003) evaluated the effectiveness of TENS for the treatment of rheumatoid arthritis of the hand. Three randomized controlled trials (n=78) met inclusion criteria. Conventional TENS (C-TENS) and acupuncture-TENS (acu-TENS) were compared to either placebo or each other. Pain outcomes on the effect of TENS were conflicting. Acu-TENS was beneficial for reducing pain intensity and improving muscle power scores compared to placebo. No clinical benefit on pain was reported with C-TENS compared to placebo. C-TENS resulted in a clinical benefit on the patients' assessment of change compared to acu-TENS. The authors concluded that more well designed studies with a standardized protocol and adequate numbers of subjects were needed to fully identify the effect of TENS for the treatment of RA of the hand.

Dissanayaka et al. (2016) compared the effectiveness of transcutaneous electrical nerve stimulation and interferential therapy (IFT) both in combination with hot pack, myofascial release, active range of motion exercise, and a home exercise program on myofascial pain syndrome patients with upper trapezius myofascial trigger point. Following randomization of patients into three groups (hot pack, active range of motion exercises, myofascial release, and a home exercise program with postural advice), transcutaneous electrical nerve stimulation-standard care and IFT-standard care-were administered eight times during 4 weeks at regular intervals. Pain intensity and cervical range of motions (cervical extension, lateral flexion to the contralateral side, and rotation to the ipsilateral side) were measured at baseline, immediately after the first treatment, before the eighth treatment, and 1 week after the eighth treatment. Immediate and short-term improvements were marked in the transcutaneous electrical nerve stimulation group (n = 35) compared with the IFT group (n = 35) and the control group (n = 35) with respect to pain intensity and cervical range of motions ( $P < 0.05$ ). The IFT group showed significant improvement on these outcome measurements than the control group did ( $P < 0.05$ ). Authors concluded that TENS with standard care facilitates recovery better than IFT does in the same combination.

Page et al. (2016) completed a Cochrane Database Systematic Review on electrotherapy modalities for rotator cuff disease. Examples included therapeutic ultrasound, low-level laser therapy (LLLT), transcutaneous electrical nerve stimulation (TENS), and pulsed electromagnetic field therapy (PEMF). These modalities are usually delivered as components of a physical therapy intervention. Authors synthesized the available evidence regarding the benefits and harms of electrotherapy modalities for the treatment of people with rotator cuff disease. Randomized controlled trials (RCTs) and quasi-randomized trials, including adults with rotator cuff

disease (e.g. subacromial impingement syndrome, rotator cuff tendinitis, calcific tendinitis), and comparing any electrotherapy modality with placebo, no intervention, a different electrotherapy modality or any other intervention (e.g. glucocorticoid injection) were included. Trials investigating whether electrotherapy modalities were more effective than placebo or no treatment, or were an effective addition to another physical therapy intervention (e.g. manual therapy or exercise) were the main comparisons of interest. Main outcomes of interest were overall pain, function, pain on motion, patient-reported global assessment of treatment success, quality of life and the number of participants experiencing adverse events. Most trials (n = 43) included participants with rotator cuff disease without calcification (four trials included people with calcific tendinitis). Sixteen (34%) trials investigated the effect of an electrotherapy modality delivered in isolation. Only 23% were rated at low risk of allocation bias, and 49% were rated at low risk of both performance and detection bias (for self-reported outcomes). The trials were heterogeneous in terms of population, intervention and comparator, so none of the data could be combined in a meta-analysis. Authors were uncertain whether transcutaneous electrical nerve stimulation (TENS) was more or less effective than glucocorticoid injection with respect to pain, function, global treatment success and active range of motion because of the very low quality evidence from a single trial. Authors concluded that uncertainty exists as to whether TENS is superior to placebo, and whether any electrotherapy modality provides benefits over other active interventions (e.g. glucocorticoid injection) because of the very low quality of the evidence. Further trials of electrotherapy modalities for rotator cuff disease should be based upon a strong rationale and consideration of whether or not they would alter the conclusions of this review.

In an article by Vance et al. (2014) titled “Using TENS for pain control: the state of the evidence,” Transcutaneous electrical nerve stimulation (TENS) is described as a nonpharmacological intervention that activates a complex neuronal network to reduce pain by activating descending inhibitory systems in the central nervous system to reduce hyperalgesia. Within the article, authors describe the current mechanisms of TENS reduction on analgesia, which is thought to be more complex than previously described. More specifically, TENS activates a complex neuronal network to result in a reduction in pain. At frequencies and intensities used clinically, TENS activates large diameter afferent fibers. This afferent input is sent to the central nervous system to activate descending inhibitory systems to reduce hyperalgesia. Specifically, blockade of neuronal activity in the periaqueductal gray (PAG), rostral ventromedial medulla (RVM) and spinal cord inhibit the analgesic effects of TENS showing that TENS analgesia is maintained through these pathways. In parallel, studies in people with fibromyalgia show that TENS can restore central pain modulation, a measure of central inhibition. Therefore, TENS appears to reduce hyperalgesia through both peripheral and central mechanisms. Authors do report that the evidence for TENS efficacy is conflicting. Sluka et al. (2013) suggests that certain factors should be considered when evaluating the research. These include dosing of TENS, negative interactions with long-term opioid use, the population and outcome assessed, timing of outcome measurement, and comparison groups. Population-specific systemic reviews and meta-analyses are emerging, indicating both high frequency (HF) and low frequency (LF) TENS being shown to provide analgesia, specifically when applied at a strong, non-painful intensity. They conclude that additional research is necessary to determine if TENS has effects specific to mechanical stimuli and/or beyond reduction of pain and will improve activity levels, function and quality of life. These authors are considered experts in the area of TENS research and they offer these interesting practice points:

- High frequency (HF) and low frequency (LF) transcutaneous electrical nerve stimulation (TENS) activate different opioid receptors. Both applications have been shown to provide analgesia specifically when applied at a strong, non-painful intensity. HF TENS may be more effective for people taking opioids.
- Effective analgesia for chronic pain conditions may be limited by the development of tolerance to TENS if repeated application of either LF or HF TENS at the same frequency and intensity is used daily (i.e., same dose). Strategies to prolong analgesia may include varying these parameters.
- Targeting the use of TENS during movement or activity may be most beneficial.
- TENS may be effective in restoration of central pain modulation, a measure of central inhibition.
- A clearer picture of TENS effectiveness will emerge as trials with attention to optimal dosing and appropriate outcome measures increase in numbers.

Gibson et al. (2019) provided an overview of evidence from Cochrane Reviews of the effectiveness of TENS to reduce pain in adults with chronic pain (excluding headache or migraine). They included nine reviews investigating TENS use in people with defined chronic pain or in people with chronic conditions associated with ongoing pain. The evidence reported within each review was consistently rated as very low quality. since we

would predict these different comparisons may be estimating different true effects. Authors found the methodological quality of the reviews was good, but quality of the evidence within them was very low. They were therefore unable to conclude with any confidence that, in people with chronic pain, TENS is harmful, or beneficial for pain control, disability, health-related quality of life, use of pain-relieving medicines, or global impression of change. Pietrosimone et al. (2020) aimed to determine the effect of TENS + therapeutic exercise (TE) on patient-reported function, quadriceps strength, and voluntary activation, as well as physical performance compared with sham TENS + TE (Sham) and TE alone in individuals with symptomatic knee OA and quadriceps voluntary activation failure (QVAF). Ninety individuals participated in a double-blinded randomized controlled trial. Everyone received 10 standardized TE sessions of physical therapy. TENS + TE and Sham groups applied the respective devices during all TE sessions and throughout activities of daily living over 4 wk. Improvements in WOMAC subscales, quadriceps strength, and voluntary activation, 20-m walk times, chair-stand repetitions, and stair-climb time were found at post 1 and post 2 compared with baseline for all groups ( $P < 0.05$ ). WOMAC Pain and Stiffness improved in the TENS + TE group compared with TE alone at post 1 ( $P < 0.05$ ); yet, no other between-group differences were found. Authors concluded that TE effectively improved patient-reported function, quadriceps strength, and voluntary activation, as well as physical performance in individuals with symptomatic KOA and QVAF, but augmenting TE with TENS did not improve the benefits of TE.

A Best Practices for Chiropractic Management of Patients with Chronic Musculoskeletal Pain: A Clinical Practice Guideline authored by Hawk et al. (2020), for chronic low back pain, TENS or interferential current may be beneficial as part of a multimodal approach, at the beginning of treatment to assist the patient in becoming or remaining active. For chronic neck pain, they recommend TENS and interferential current in the same manner as for chronic low back pain.

Rapazo et al. (2021) investigated the effectiveness of electrical stimulation (ES) for neck pain (NP). Main results showed evidence of moderate quality that ES combined with other intervention significantly decreases the pain intensity compared to other intervention immediately post-treatment and at short-term follow-up; evidence of low quality showed significant effects of ES combined with other intervention in decreasing neck disability compared to other intervention immediately post-treatment; evidence of very-low quality that ES increased the pressure pain threshold compared to placebo immediately post-treatment and that ES + other intervention also increased the pressure pain threshold compared to other intervention at short-term follow-up. Authors concluded that ES combined with other intervention seems to be useful to relieve pain and to improve disability in people with NP, however, more studies are needed.

Dias et al. (2021) compared the immediate analgesic effect of transcutaneous nerve stimulation (TENS) and interferential current (IFC), with different combinations of parameters, in individuals with chronic low back pain (CLBP). 280 individuals with CLBP were included in the study, both genders, randomized in 8 groups. All individuals underwent a single application of TENS or IFC for 30min. The assessments were carried out prior to the intervention, as well as immediately after, with the following outcomes: pain intensity (Numeric Pain Rating Scale-NPRS), qualitative pain characteristics (McGill Pain Questionnaire-MPQ), and pressure pain threshold (PPT) by pressure algometry (PA) in 4 points of the low back region. Authors concluded that both TENS and IFC presented immediate analgesic effect in CLBP, with emphasis on the interferential current of 4 KHz modulated at 100Hz.

According to the National Institute for Health and Care Excellence (NICE) review (2021), they report the following for TENS:

- TENS versus sham TENS and usual care
  - Quality of life
    - Moderate quality evidence from 1 study with 202 participants showed no clinically important difference between TENS and sham TENS at  $\leq 3$  months.
    - Quality of life Moderate to low quality evidence from 1 study with 202 participants showed no clinically important difference between TENS and usual care at  $\leq 3$  months.
  - Pain reduction
    - Very low-quality evidence from 2 studies with 242 participants showed a clinically important difference for TENS compared to sham TENS at  $\leq 3$  months.
    - Moderate quality evidence from 1 study with 40 participants showed a clinically important difference for TENS at  $> 3$  months compared to sham TENS.
    - Low quality evidence from 1 study with 202 participants showed no clinically important difference between TENS and usual care at  $\leq 3$  months.

- Physical function
  - High quality evidence from 1 study with 202 participants showed no clinically important difference between TENS and sham TENS at  $\leq 3$  months.
  - High quality evidence from 1 study with 202 participants showed no clinically important difference between TENS and usual care at  $\leq 3$  months.
- Psychological distress
  - Moderate to low quality evidence from 1 study with 202 participants showed no clinically important difference between TENS and sham TENS at  $\leq 3$  months.
  - Moderate to low quality evidence from 1 study with 202 participants showed no clinically important difference between TENS and usual care at  $\leq 3$  months.
- Pain interference
  - Low quality evidence from 1 study with 202 participants showed no clinically important difference between TENS and sham TENS at  $\leq 3$  months.
  - Low quality evidence from 1 study with 202 participants showed no clinically important difference between TENS and usual care at  $\leq 3$  months.
- Pain self-efficacy
  - High quality evidence from 1 study with 202 participants showed no clinically important difference between TENS and sham TENS at  $\leq 3$  months.
  - High quality evidence from 1 study with 202 participants showed no clinically important difference between TENS and usual care at  $\leq 3$  months.

Paley et al. (2021) critically appraised the characteristics and outcomes of systematic reviews evaluating the clinical efficacy of TENS for any type of acute and chronic pain in adults. Authors included 169 reviews consisting of eight overviews, seven hybrid reviews and 154 systematic reviews with 49 meta-analyses. Only three meta-analyses pooled sufficient data to have confidence in the effect size estimate (i.e., pooled analysis of >500 events). Lower pain intensity was found during TENS compared with control for chronic musculoskeletal pain and labour pain, and lower analgesic consumption was found post-surgery during TENS. The appraisal revealed repeated shortcomings in RCTs that have hindered confident judgements about efficacy, resulting in stagnation of evidence. Authors concluded that this appraisal reveals examples of meta-analyses with 'sufficient data' demonstrating benefit. There were no examples of meta-analyses with 'sufficient data' demonstrating no benefit. Therefore, they recommend that TENS should be considered as a treatment option.

Reichenbach et al. (2022) sought to determine the effectiveness of TENS at relieving pain and improving physical function as compared to placebo TENS, and to determine its safety, in patients with knee osteoarthritis. 220 participants with knee osteoarthritis were recruited between October 15, 2012, and October 15, 2014. Patients were randomized to 3 weeks of treatment with TENS ( $n = 108$ ) or placebo TENS ( $n = 112$ ). The primary endpoint was knee pain at the end of 3-weeks treatment assessed with the WOMAC pain subscale. Secondary outcome measures included WOMAC physical function subscale and safety outcomes. There was no difference between TENS and placebo TENS in WOMAC pain at the end of treatment, nor throughout the trial duration. Subgroup analyses did not indicate an interaction between patient/treatment characteristics and treatment effect on WOMAC pain at the end of treatment ( $P$ -interaction  $\geq 0.22$ ). The occurrence of adverse events was similar across groups, with 10.4% and 10.6% of patients reporting events in the TENS and placebo TENS groups, respectively ( $P = 0.95$ ). No relevant differences were observed in secondary outcomes. Authors concluded that TENS does not improve knee osteoarthritis pain when compared to placebo TENS. Therapists should consider other potentially more effective treatment modalities to decrease knee osteoarthritis pain and facilitate strengthening and aerobic exercise. Wu et al. (2022) evaluated the effects of Transcutaneous Electric Nerve Stimulation (TENS) on pain, function, walking ability and stiffness in people with Knee osteoarthritis (KOA). Twenty-nine studies were found (1398 people, age range 54-85, 74% are female) and fourteen were included in this review. Intervention duration was divided as short term (immediately after intervention), medium term (<four weeks) and long term ( $\geq$  four weeks). Active TENS showed greater improvement in Visual Analogue Scale (VAS) than sham TENS. Combining TENS with other interventions produced superior outcomes compared with other interventions for VAS in all the terms. In the meanwhile, TENS combined with other interventions was superior to other interventions for the pain subgroup of Western Ontario and McMaster Universities Arthritis Index in the medium term and long term. TENS combined with other interventions was superior to other interventions for function in the medium term and long term. Authors concluded that TENS could significantly relieve pain, decrease dysfunction and improve walking ability in people with KOA, but it is not effective for stiffness.

Johnson et al. (2022) investigated the efficacy and safety of transcutaneous electrical nerve stimulation (TENS) for relief of pain in adults in a systematic review and meta-analysis. The review included 381 RCTs (24, 532 participants). Pain intensity was lower during or immediately after TENS compared with placebo (moderate-certainty evidence). Methodological (eg, sample size) and pain characteristics (eg, acute vs chronic, diagnosis) did not modify the effect. Pain intensity was lower during or immediately after TENS compared with pharmacological and non-pharmacological treatments used as part of standard of care (low-certainty evidence). Levels of evidence were downgraded because of small-sized trials contributing to imprecision in magnitude estimates. Data were limited for other outcomes including adverse events which were poorly reported, generally mild and not different to comparators. Authors concluded that there was moderate-certainty evidence that pain intensity is lower during or immediately after TENS compared with placebo and without serious adverse events.

Wu et al. (2022) evaluated the effects of Transcutaneous Electric Nerve Stimulation (TENS) on pain, function, walking ability and stiffness in people with Knee osteoarthritis (KOA). Twenty-nine studies were found (1398 people, age range 54-85, 74% are female) and fourteen were included in this review. Intervention duration was divided as short term (immediately after intervention), medium term (<four weeks) and long term ( $\geq$  four weeks). Active TENS showed greater improvement in Visual Analogue Scale (VAS) than sham TENS. Combining TENS with other interventions produced superior outcomes compared with other interventions for VAS in all the terms. In the meanwhile, TENS combined with other interventions was superior to other interventions for the pain subgroup of Western Ontario and McMaster Universities Arthritis Index in the medium term and long term. TENS combined with other interventions was superior to other interventions for function in the medium term and long term. Authors concluded that TENS could significantly relieve pain, decrease dysfunction and improve walking ability in people with KOA, but it is not effective for stiffness.

Beltran-Alacreu et al. (2022) determined if the use of PENS is more effective and should be recommended when compared to TENS for the reduction of musculoskeletal pain intensity. Nine RCTs were included in the qualitative analysis, with seven of them in the quantitative analysis ( $n = 527$ ). The overall effect of PENS on pain was statistically but not clinically superior to TENS with a high level of heterogeneity. When only studies with a lower risk of bias ( $n = 3$ ) were analyzed, the heterogeneity decreased, and no difference was observed between TENS and PENS with a moderate recommendation level according to GRADE. There were no data concerning adverse effects. There is low-quality of evidence for more pain intensity reduction with PENS, but the difference was not clinically significant. However, when only studies with low risk of bias are meta-analyzed, there is a moderate quality of evidence that there is no difference when TENS or PENS is applied for pain intensity.

Evans et al. (2022) summarized the reported efficacy of transcutaneous single nerve stimulators in management of migraine frequency and severity. Fourteen studies, which treated 995 patients, met inclusion criteria, including 7 randomized controlled trials and 7 uncontrolled clinical trials. Transcutaneous nerve stimulators reduced headache frequency in episodic migraines (2.81 fewer headache days per month, 95% CI 2.18-3.43,  $I^2 = 21\%$ ) and chronic migraines (2.97 fewer headache days per month). Transcutaneous nerve stimulators reduced headache severity in episodic headaches (2.23 fewer pain scale points). Authors concluded that preventive use of transcutaneous nerve stimulators provided clinically significant reductions in headache frequency in individuals with chronic or episodic migraines. Individuals with episodic migraines also experienced a reduction in headache pain severity following preventive transcutaneous nerve stimulation.

Fertout et al. (2022) assessed the efficacy of transcutaneous electrical nerve stimulation (TENS) for the management of temporomandibular disorders (TMD) and to determine the indications and most appropriate application modalities in a systematic review. Fourteen articles were retained, corresponding to a total of 532 patients, among which, 285 had a TMD. Immediately after a TENS session, significant relief of pain (19.2% to 77%), significant functional improvement (mouth opening amplitude increased by between 8.7% and 19.46%), and reduced electromyographic activity of the anterior temporalis and masseter muscles were observed. However, studies comparing TENS to other physical medicine modalities (ultrasound and laser) reported equivalent results. Authors concluded that further randomized comparative clinical trials will be necessary to optimize the use of TENS (program, duration of sessions, duration of treatment) for different types of TMD.

Vance et al. (2022) addressed the continued uncertainty about the clinical efficacy of TENS to alleviate pain, despite years of research and note that this uncertainty is related to the quality of the clinical trials included in systematic reviews. This summary of the evidence includes only trials with pain as the primary outcome. In comparison with their 2014 review, there appears to be improvement in adverse events and parameter reporting. Importantly, stimulation intensity has been documented as critical to therapeutic success.

Examinations of the outcomes beyond resting pain, analgesic tolerance, and identification of TENS responders remain less studied areas of research. This literature review supports the conclusion that TENS may have efficacy for a variety of acute and chronic pain conditions, although the magnitude of the effect remains uncertain due to the low quality of existing literature. In order to provide information to individuals with pain and to clinicians treating those with pain, authors suggest that resources for research should target larger, high-quality clinical trials including an adequate TENS dose and adequate timing of the outcome and should monitor risks of bias. Systematic reviews and meta-analyses should focus only on areas with sufficiently strong clinical trials that will result in adequate sample size.

Davison et al. (2022) systematically reviewed and evaluated available literature examining the effectiveness of using electrical stimulation to promote clinical outcomes after hip fractures. They identified 432 records through database searching. Initial screening indicated 24 articles were appropriate for full-text review, and four articles met the inclusion criteria. In included studies, electrical stimulation (i.e. TENS) reduced pain, improved range of motion (ROM), and accelerated functional recovery immediately after hip fracture. Conflicting evidence existed when using neuromuscular electrical stimulation to improve muscle strength and other functional outcomes (e.g. mobility); however, nine experts advised that longer-term interventions might be necessary to achieve significant improvement in muscle strength. Authors concluded that available evidence, albeit limited, supports the early application of noninvasive electrical stimulation (e.g. TENS) for improving clinical outcomes (i.e. reducing pain, improving ROM, and accelerating functional recovery after hip fractures). They could not find conclusive evidence on the effectiveness of using electrical stimulation to improve muscle strength. This review establishes the need for future additional high-quality trials in this field.

Leemans et al. (2022) estimated the effects of musculoskeletal rehabilitation interventions on movement-evoked pain and to explore the assessment methods/protocols used to evaluate movement-evoked pain in adults with musculoskeletal pain. Meta-analysis was conducted for outcomes with homogeneous data from at least 2 trials. The mean change in movement-evoked pain was the primary outcome measure. Thirty-eight trials were included, and 60 different interventions were assessed. There was moderate-certainty evidence of a beneficial effect of exercise therapy compared to no treatment on movement-evoked pain in adults with musculoskeletal pain. There was low-certainty evidence of a beneficial effect of transcutaneous electrical nerve stimulation compared to no treatment. There was no benefit of transcutaneous electrical nerve stimulation when compared to sham transcutaneous electrical nerve stimulation.

### **Microcurrent Electrical Nerve Stimulation**

There is insufficient evidence in the published peer-reviewed scientific literature to support the safety and effectiveness of MENS including frequency specific microcurrent (FSM). Studies include small patient populations and short-term follow-ups with conflicting outcomes and in some cases reported outcomes were no better than placebo (Rajpurohit et al., 2010; Zuim et al., 2006). More recently, microcurrent, using very small electrical devices contained within wound dressings, has been evaluated as a therapy to speed the closure of chronic wounds. However, research published to date has not produced findings that suggest this form of ES can accelerate wound closure (Houghton, 2014). Nair (2018) did not see some positive findings for wound healing, however more research is needed to confirm results. Iijima and Takahashi (2021) summarized the level of knowledge regarding the effects of microcurrent therapy (MCT) on musculoskeletal pain in adults. Randomized controlled trials (RCTs) investigating the effects of MCT on musculoskeletal pain were included. Additionally, non-RCTs were included to assess the adverse events. The primary outcomes were pain and adverse events related to MCT. A comprehensive assessment of 4 RCTs and 5 non-RCTs that met the inclusion criteria revealed that MCT significantly improved shoulder pain (1 study, 40 patients) and knee pain (1 study, 52 patients) compared with sham MCT without any severe adverse events. MCT has clinically significant benefits for knee pain. This study also revealed a clinically significant placebo response in treating knee pain. This evidence highlights the substantial effect of placebo response in clinical care. Authors concluded that the findings of this meta-analysis highlight the effect of placebo response in treating knee pain. MCT is a potential, core nonpharmacologic treatment option in clinical care with minimal adverse events and should be further investigated.

### **H-WAVE®**

There is insufficient evidence in the published peer reviewed scientific literature to support the safety and effectiveness of the H-WAVE® electrical stimulators. Blum et al. (2008) conducted a systematic review and meta-analysis of randomized and nonrandomized controlled trials to evaluate the safety and efficacy of H-

WAVE® therapy. Five studies (n=6535) met inclusion criteria. H-WAVE® was shown to decrease pain across various chronic soft tissue inflammation and neuropathic pain conditions, decrease pain medication intake (n=2 studies) and increase functionality (n=2 studies). However, author-noted limitations of the studies included the heterogeneity of the studies, inconsistency of the effects (e.g., reduction in pain medication, functionality), data were obtained from cross-sectional studies, data were subjective in nature (i.e., there were no formal examination findings, test results and/or laboratory values), various outcome measures, potential selection bias of publications for this review, and due to a lack of reported data it was not possible to statistically evaluate the safety of the therapy. Williamson et al. (2021) systematically searched human clinical studies on H-Wave® device stimulation (HWDS) was conducted as well as a comprehensive review of articles articulating possible HWDS mechanisms of action. Studies unrelated to H-Wave were excluded. Multiple clinical studies have reported significant benefits for diabetic and non-specific neuropathic pain, where function also improved, and pain medication usage substantially dropped. Authors concluded that low- to moderate-quality HWDS studies have reported reduced pain, restored functionality, and lower medication use in a variety of disorders, although higher-quality research is needed to verify condition-specific applicability. HWDS has enough reasonable evidence to be considered as an adjunctive component of non-opioid multi-modal pain management, given its excellent safety profile and relative low cost. It is important to consider that two authors have a conflict of interest as they are consultants for Electronic Waveform Lab Inc. and have an interest in a positive outcome.

### **Threshold Electrical Stimulation (TES)**

Dali et al. (2002) sought to determine whether a group of stable children with cerebral palsy would improve their motor skills after 12 months of TES. Two thirds received active and one third received inactive stimulators. Fifty seven of 82 outpatients who were able to walk at least with a walker, completed all 12 months of treatment. Results demonstrated that there was no significant difference between active and placebo treatment in any of the tested groups, nor combined. Authors concluded that TES in these patients did not have any significant clinical effect during the test period. Kerr et al. (2006) investigated the efficacy of NMES and TES in strengthening the quadriceps muscles of both legs in children with cerebral palsy (CP). Sixty children were randomized to one of the following groups: NMES (n=18), TES (n=20), or placebo (n=22). Thirty-four children walked unaided, 17 used posterior walkers, six used crutches, and the remaining three used sticks for mobility. Peak torque of the left and right quadriceps muscles, gross motor function, and impact of disability were assessed at baseline and end of treatment (16wks), and at a 6-week follow-up visit. No statistically significant difference was demonstrated between NMES or TES versus placebo for strength or function. Statistically significant differences were observed between NMES and TES versus placebo for impact of disability at the end of treatment, but only between TES and placebo at the 6-week follow-up. In conclusion, further evidence is required to show whether NMES and/or TES may be useful as an adjunct to therapy in ambulatory children with diplegia who find resistive strengthening programmes difficult.

### **Interferential Current (IFC)**

Studies for IFC are primarily in the form of case reports, case series and some randomized controlled trials with small patient populations, short-term treatment sessions and short-term follow-ups. Randomized controlled trials with large patient populations and long-term follow-ups comparing IFT to established treatment options are lacking. The California Technology Assessment Forum (2005) evaluated the literature on IFT for the treatment of musculoskeletal pain and concluded that this treatment modality has not been shown to be as beneficial as alternative treatments such as nonsteroidal anti-inflammatory drugs and exercise therapy. Although IFT was found to be a generally safe technique, it did not meet the CTAF technology assessment criteria for the treatment of musculoskeletal pain. Fuentes et al. (2010) conducted a systematic review and meta-analysis of randomized controlled trials (n=20) to evaluate the pain-reducing effectiveness of IFC in the management of musculoskeletal pain. Twenty studies met inclusion criteria. Seven studies assessed IFC for joint pain (e.g., osteoarthritis), nine for muscle pain (e.g., low back pain, neck pain), three for soft tissue shoulder pain (e.g., tendinitis) and one for postoperative pain. Three studies were considered to be of poor methodological quality, 14 of moderate quality and three of high quality. Methodological issues included small sample sizes, heterogeneity of patient population, inappropriate handling of withdrawals and dropouts, and lack of appropriate randomization, concealment of allocation and blinding of patients and assessors. Fourteen studies (n=1114) were used for meta-analysis. Only three studies reported adverse events (e.g., blisters, burns, bruising, swelling). The authors concluded that the analgesic effect that IFC is superior to that of the concomitant interventions was unknown; IFC alone was not significantly better than placebo or other therapy at discharge or follow-up; the heterogeneity across studies and methodological limitations prevented conclusive statements regarding analgesic efficacy; and the results should be viewed with caution due to the limited number of studies

that used IFC as a monotherapy. The American College of Physicians and the American Pain Society Joint Clinical Practice Guideline for the Diagnosis and Treatment of LBP (Chou and Huffman 2007) concluded that there was not enough evidence to support the use of interferential therapy, TENS, traction, ultrasound, or short wave diathermy for acute or chronic LBP. These results were based on systematic reviews and randomized trials of one or more of the aforementioned therapies for treatment of acute or chronic LBP that reported pain outcomes, back specific function, general health status, work disability or patient satisfaction. In a review by Poitras and Brosseau (2008), they determined that due to limited studies of sufficient quality, no recommendations could be made for the use of ultrasound, interferential current, or electrical muscle stimulation for the treatment of chronic LBP. Facci et al. (2011) compared the effects of TENS and interferential current among patients with nonspecific chronic low back pain. One hundred and fifty patients were randomly divided into three groups: TENS (group 1), interferential current (group 2) and controls (group 3). The patients designated for electrotherapy received ten 30-minute sessions, while the control group remained untreated. All patients and controls were evaluated before and after treatment using a visual analog scale and the McGill Pain and Roland Morris questionnaires, and regarding their use of additional medications. Results showed no statistically significant difference between the TENS and interferential current groups. The only difference was found between these groups and the controls, with noted improvement in outcome measures for the treatment groups. According to the AHRQ publication on Non-Invasive Treatments for Low Back Pain (2016), insufficient evidence from four trials exists regarding the effectiveness of interferential therapy versus other interventions, or interferential therapy plus another intervention versus the other interventions alone for low back pain, due to methodological limitations and imprecision. According to the American College of Physician's Noninvasive Treatments for Acute, Subacute, and Chronic Low Back Pain clinical practice guideline (2017), evidence was insufficient to determine the effectiveness of electrical muscle stimulation and inferential therapy.

Rutjes et al. (2009) conducted a systematic review of randomized or quasi-randomized controlled trials of electrical stimulation, including IFT (n=4 studies), for the treatment of osteoarthritis of the knee. Due to the poor methodological and reporting quality of the studies, the effectiveness of IFT could not be confirmed. Zeng et al. (2015) investigated the efficacy of different electrical stimulation (ES) therapies in pain relief of patients with knee osteoarthritis (OA). 27 trials and six kinds of ES therapies, including high-frequency transcutaneous electrical nerve stimulation (h-TENS), low-frequency transcutaneous electrical nerve stimulation (l-TENS), neuromuscular electrical stimulation (NMES), interferential current (IFC), pulsed electrical stimulation (PES), and noninvasive interactive neurostimulation (NIN), were included. IFC was the only significantly effective treatment in terms of both pain intensity and change pain score at last follow-up time point when compared with the control group. Meanwhile, IFC showed the greatest probability of being the best option among the six treatment methods in pain relief. However, the evidence of heterogeneity and the limitation in sample size of some studies could be a potential threat to the validity of results. Authors also state that although the recommendation level of the other ES therapies is either uncertain (h-TENS) or not appropriate (l-TENS, NMES, PES and NIN) for pain relief, it is likely that none of the interventions is dangerous. Almeida et al. (2018) investigated the effects of transcutaneous electrical nerve stimulation and interferential current on acute and chronic pain. Eight studies with a pooled sample of 825 patients were included. In general, both transcutaneous electrical nerve stimulation and interferential current improved pain and functional outcomes without a statistical difference between them. Authors concluded that transcutaneous electrical nerve stimulation and interferential current have similar effects on pain outcome. The low number of studies included in this meta-analysis indicates that new clinical trials are needed.

Kadi et al. (2019) evaluated IFS for treating pain after total knee arthroplasty surgery. A total of 113 individuals were randomized to IFS (n=57) or sham treatment (n=56). There were 98 individuals (87%) who completed the study. After 30 days, there was no significant difference between groups in pain assessed by a VAS, 0.278. Pain medication use (paracetamol) also did not differ significantly between groups after treatment and neither did outcome measures assessing range of motion or edema. In this study, IFS was not beneficial at improving outcomes after total knee arthroplasty. Hussein et al. (2022) aimed to analyze the recently available information regarding the efficacy of IFC in alleviating the pain of musculoskeletal origin. This review included 35 trials of variable methodological quality from which 19 trials were selected for the meta-analysis. In general, IFC alone versus placebo demonstrated a significant pain-relieving effect. On the other hand, IFC showed no significant difference when added to standard treatment compared to placebo plus standard treatment or standard treatment alone. Similarly, IFC showed no significant difference when compared to other single interventions (laser, TENS, cryotherapy). Authors concluded that IFC alone is better than placebo at discharge. However, the low number of studies raises suspicions about this conclusion. IFC alone or added to other interventions is not

more effective than comparative treatments in relieving musculoskeletal pain. Rampazo et al. (2022) discussed the literature findings on the analgesic efficacy of IFC therapy. Authors concluded that according to the literature, IFC therapy shows significant analgesic effects in patients with neck pain, low back pain, knee osteoarthritis and post-operative knee pain. Most of the IFC parameters seem not to influence its analgesic effects. We encourage further studies to investigate the mechanism of action of IFC therapy.

Chen et al. (2022) conducted a systematic review and meta-analysis to assess the effectiveness of interferential current therapy (IFC) in patients with knee osteoarthritis. They included randomized controlled trials (RCTs) in which IFC was applied to knee osteoarthritis patients and the outcomes of pain scores or functional scales were assessed. Ten RCTs with 493 patients met the inclusion criteria. Nine RCTs were included in the meta-analysis. The IFC groups exhibited significant improvements relative to the control groups for short-term pain scores, long-term pain scores, and short-term Western Ontario and McMaster Universities Osteoarthritis Index scores. All included studies did not observe any obvious adverse effects of IFC. IFC can be recommended as a treatment for knee osteoarthritis because it improves short- and long-term pain and short-term function. However, large-scale and high-quality RCTs with longer follow-up are required to establish an appropriate standardized treatment.

### **High Volt Galvanic Stimulation (HVGS)**

The few studies identified in the literature addressing HVGS were mostly randomized clinical trials and case studies published before 1997 with small patient populations and short-term follow-up. Patient selection criteria were lacking. More recently, Snyder et al. (2010) systematically reviewed the basic-science literature regarding the effects of high-voltage pulsed stimulation (HVPS) for edema control. Included studies investigated HVPS and its effect on acute edema formation and included outcome measures specific to edema. Eleven studies met the inclusion criteria. Studies were critiqued by electrical stimulation treatment parameters: mode of stimulation, polarity, frequency, duration of treatment, voltage, intensity, number of treatments, and overall time of treatments. According to Snyder et al., (2010), the available evidence indicates that HVPS administered using negative polarity, pulse frequency of 120 pulses/s, and intensity of 90% visual motor contraction may be effective at curbing edema formation. In addition, according to authors, evidence suggests that treatment should be administered in either four 30-min treatment sessions (30-min treatment, 30-min rest cycle for 4 h) or a single, continuous 180-min session to achieve the edema-suppressing effects. Often such treatment occurs in an athletic training room for college athletes and may not be feasible in an outpatient clinical setting. Authors suggest that findings supported by the basic science research provides a general list of treatment parameters that may successfully manage the formation of edema after acute injury in animal subjects. They believe this should facilitate further research related to HVPS and the effects on edema in humans. At this time, there is insufficient evidence in the published peer reviewed scientific literature to support the safety and efficacy of HVG/HVPS stimulation.

### **PENS and PNT**

There is insufficient evidence in the published peer-reviewed literature to support the safety and effectiveness of PENS or PNT as a treatment option for chronic pain. Overall, studies have included small patient populations and short term follow-ups. For low back pain, most of the literature is of poor quality with all trials evaluating chronic low back pain. In a technology brief, Hayes (2017) investigated the effectiveness of PENS for the treatment of low back pain (LBP). Three randomized controlled trials (n=34 to 200) evaluated the efficacy and safety of PENS for chronic LBP (CLBP) in adults and one study evaluated PNT for subacute radiating LBP. Hayes rated the studies as very low-quality of evidence. There was no clinically significant improvement with the use of PENS. When compared with other therapies, PENS monotherapy was favored over treatment with PENS followed by TENS or TENS alone at one month; however, the difference was not maintained at two months. Another study reported no difference in outcomes with PENS vs. sham. There is insufficient evidence to support PENS for the treatment of LBP. Weiner et al. (2008) conducted a randomized controlled trial (n=200) to evaluate the efficacy of PENS in adults with chronic low back pain. Patients were randomized to either 1) PENS, 2) brief electrical stimulation to control for treatment expectance (control-PENS), 3) PENS plus general conditioning and aerobic exercise (GCAE) or to 4) control-PENS plus GCAE. Treatment was delivered twice a week for six weeks to the 50 participants in each group. All groups reported significantly reduced pain (McGill Pain Questionnaire short form) and disability and improved gait velocity, which was sustained at six months. Significantly fewer fear avoidance beliefs were reported in the CGAE group compared to the non-CGAE group. Comparable reduced pain and function were reported by the PENS and control-PENS group, whether delivered for five minutes or 30 minutes. Thus, the exact dose of electrical stimulation needed for analgesia could not be determined. PENS and

GCAE were more effective than PENS alone in reducing fear avoidance beliefs, but not in reducing pain or in improving physical function. There was a statistically significant improvement in chair rise time in the control-PENS plus CGAE compared to control-PENS alone. The overall drop-out rate was 8%. In the Agency for Healthcare Research and Quality (AHRQ) publication “Noninvasive Treatments for Low Back Pain” by Chou et al. (2016), the two studies on PENS that were of fair quality contradicted one another, as one found that PENS plus exercise was superior to sham plus exercise, while the other did not. Some studies looked at LBP with radicular signs while others did not or were unclear. Overall, the literature doesn’t support PENS for treatment of chronic low back pain without radicular symptoms. There was insufficient evidence to determine effects of PENS versus sham, PENS plus exercise versus exercise alone, or PENS versus other interventions (TENS), due to methodological limitations and imprecision. Harms were poorly reported in trials of PENS.

Kang et al. (2007) conducted a single-blinded, randomized study of 63 patients with knee pain secondary to osteoarthritis. Twenty-eight patients were randomly assigned to the sham group and 35 to the live treatment group. The study investigated the efficacy of PNT in reducing knee pain and medication consumption during the first week following treatment. Pain levels were rated on a 100-mm visual analog pain scale. The live group had greater efficacy than the sham group in all time periods; however, only in the immediate post-treatment period did it reach statistical significance ( $p=0.0361$ ). The overall median pain intensity difference over all periods was 14.5 for the live group and 6.5 for the sham group and reached statistical significance. At one week follow-up, the live group reported significantly less medication use than the sham group. Plaza-Manzano et al. (2020) evaluated the effects of percutaneous electrical stimulation (PENS) alone or as an adjunct with other interventions on pain and related disability in musculoskeletal pain conditions. Sixteen studies were included and included heterogeneous musculoskeletal conditions with short- or midterm follow-ups. The risk of bias was generally low; but the heterogeneity of the results downgraded the level of evidence. Authors concluded that there is low level of evidence suggesting the effects of PENS alone or in combination for pain, but not related disability, in musculoskeletal pain.

Beltran-Alacreu et al. (2022) aimed to determine if the use of PENS was more effective and should be recommended when compared to TENS for the reduction of musculoskeletal pain intensity. Studies published until 31/12/2020, comparing the effectiveness of PENS and TENS, were considered. The main outcome was pain assessed with a visual analog scale or numerical pain rating scale. Nine RCTs were included in the qualitative analysis, with seven of them in the quantitative analysis ( $n = 527$ ). The overall effect of PENS on pain was statistically but not clinically superior to TENS with a high level of heterogeneity. When only studies with a lower risk of bias ( $n = 3$ ) were analyzed, no difference was observed between TENS and PENS with a moderate recommendation level according to GRADE. There were no data concerning adverse effects. There was low-quality of evidence for more pain intensity reduction with PENS, but the difference was not clinically significant. However, when only studies with low risk of bias are meta-analyzed, there was a moderate quality of evidence that there is no difference when TENS or PENS is applied for pain intensity. According to National Institute for Health and Care Excellence (NICE), regarding PENS:

- PENS versus sham PENS
  - Quality of life
    - Low quality evidence from 1 study with 89 participants showed a clinically important benefit of PENS compared to sham PENS at  $\leq 3$  months.
    - Very low to low quality evidence from 1 study with 24 participants showed a clinically important benefit of PENS compared to usual care at  $\leq 3$  months.
  - Pain reduction
    - Low quality evidence from 1 study with 89 participants showed a clinically important benefit of PENS compared to sham PENS at  $\leq 3$  months.
    - Low quality evidence from 1 study with 24 participants showed a clinically important benefit of PENS compared to usual care at  $\leq 3$  months.

## NMES and FES

Electric stimulated muscle contraction/neuromuscular electric stimulation (NMES) has been found to enhance muscle function post surgically. Patients who have received an ACL reconstruction have demonstrated accelerated recovery and greater muscle function when NMES is used in combination with exercise; however the impact on functional outcomes is inconsistent (Cameron, 2017). Similar results were noted with knee OA patients and for other inflammatory conditions of the knee. Most research studied the use of NMES on the quadriceps muscle, however clinically NMES may be used for other joints and muscle groups (Cameron, 2017). NMES has been shown to be part of an effective rehabilitative regimen for patients following ligament/knee

surgery. It may help prevent muscle atrophy associated with knee immobilization, may enable patients to ambulate sooner, and may reduce the use of pain medication as well as length of hospital stay (Arvidsson, 1986; Lake, 1992; Gotlin et al, 1994; Snyder-Mackler et al, 1991 and 1995). Bax et al (2005) systematically reviewed the available evidence for the use of NMES in increasing strength of the quadriceps femoris. The authors concluded that limited evidence suggests that NMES can improve strength in comparison with no exercise, but volitional exercises appear more effective in most situations. The authors' cautious conclusions reflect the general poor quality of the included studies. It is also important to understand that at the time NMES is used, it is to re-education the neuromuscular system and engage more motor units with muscle contraction. Given this, the mechanism of strength increase is likely due to improved neuromuscular action vs. a true strength increase of the muscle.

Monaghan et al. (2010) completed a Cochrane review regarding the effectiveness of NMES as a means of increasing quadriceps strength in patients before and after total knee replacement. Only two studies were identified for inclusion in the review. No significant differences were reported in either study for maximum voluntary isometric torque or endurance between the NMES group and the control group but significantly better quadriceps muscle activation was reported in the exercise and neuromuscular stimulation group compared with the exercise group alone in the second study. This difference was significant at the mid training (six week) time point but not at the twelfth week post training time point. Both studies carried a high risk of bias. Mean values were not given for strength, endurance, cross sectional area or quality of life. Pain outcomes, patient satisfaction or adverse effects were not reported in either study. The results were presented as percentage improvements from baseline and the number of subjects in each group was unclear. Authors concluded that the studies found in this review do not permit any conclusions to be made about the application of neuromuscular stimulation for the purposes of quadriceps strengthening before or after total knee replacement. At that time the evidence for the use of neuromuscular stimulation for the purposes of quadriceps strengthening in this patient group is unclear.

Kim et al. (2010) performed a systematic review of RCTs assessing the effects of NMES on quadriceps strength, functional performance, and self-reported function after ACL reconstruction. Eight randomized controlled trials were included. Authors concluded that NMES combined with exercise may be more effective in improving quadriceps strength than exercise alone, whereas its effect on functional performance and patient-oriented outcomes is inconclusive. Inconsistencies were noted in the NMES parameters and application of NMES. Imoto et al. (2011) systematically evaluated the effectiveness of electrical stimulation on rehabilitation after ligament and meniscal injuries. Seventeen studies evaluating ES after anterior cruciate ligament reconstruction and two studies evaluating ES after meniscectomy were included. There was a statistically significant improvement in quadriceps strength through ES and in functional outcomes six to eight weeks after surgical reconstruction of the anterior cruciate ligament. Authors concluded that there is evidence that ES coupled with conventional rehabilitation exercises may be effective in improving muscle strength and function two months after surgery. Maddocks et al. (2013) evaluated the effectiveness of NMES for improving muscle strength in adults with advanced disease and to examine the acceptability and safety of NMES, and changes in muscle function (strength or endurance), muscle mass, exercise capacity, breathlessness and health-related quality of life. They included randomized controlled trials (RCTs) in adults with advanced chronic obstructive pulmonary disease (COPD), chronic heart failure, cancer or human immunodeficiency virus/acquired immunodeficiency syndrome (HIV/AIDS) comparing a program of NMES as a sole or adjunct intervention to no treatment, placebo NMES or an active control. Eleven studies involving a total of 218 participants met the inclusion criteria across COPD, chronic heart failure and thoracic cancer. Authors concluded NMES appears an effective means of improving muscle weakness in adults with progressive diseases such as COPD, chronic heart failure and cancer. Further research is needed to confirm findings and determine most effective parameters.

Bemner et al. (2016) completed a critically appraised topic on the effectiveness of neuromuscular electrical stimulation in improving voluntary activation of the quadriceps. Four randomized controlled trials (RCTs) met the inclusion criteria and were included. Of the included studies, one reported statistically significant improvements in quadriceps voluntary activation in the intervention group relative to a comparison group, but the statistical significance was not true for another study consisting of the same sample of participants with a different follow-up period. One study reported a trend in the NMES group, but the between group differences were not statistically significant in three of the four RCTs. Current evidence does not support the use of NMES for the purpose of enhancing quadriceps voluntary activation in patients with orthopedic knee conditions. There is level B evidence that the use of NMES alone, or in conjunction with therapeutic exercise, does not enhance

quadriceps voluntary activation in patients with orthopedic knee conditions (e.g., anterior cruciate ligament injuries, osteoarthritis, total knee arthroplasty).

Jones et al. (2016) updated a Cochrane Database review on the effectiveness of neuromuscular electrical stimulation for quadriceps muscle weakness in adults with advanced disease. Programs of NMES appear to be acceptable to patients and have led to improvements in muscle function, exercise capacity, and quality of life. However, estimates regarding the effectiveness of NMES based on individual studies lack power and precision. Randomized controlled trials in adults with advanced chronic respiratory disease, chronic heart failure, cancer, or HIV/AIDS comparing a program of NMES as a sole or adjunct intervention to no treatment placebo NMES, or an active control were included. Eighteen studies (20 reports) involving a total of 933 participants with COPD, chronic respiratory disease, chronic heart failure, and/or thoracic cancer met the inclusion criteria for this update, an additional seven studies since the previous version of this review. All but one study that compared NMES to resistance training compared a program of NMES to no treatment or placebo NMES. Most studies were conducted in a single center and had a risk of bias arising from a lack of participant or assessor blinding and small study size. The quality of the evidence using GRADE comparing NMES to control was low for quadriceps muscle strength, moderate for occurrence of adverse events, and very low to low for all other secondary outcomes. The included studies reported no serious adverse events and a low incidence of muscle soreness following NMES. NMES led to a statistically significant improvement in quadriceps muscle strength. An increase in muscle mass was also observed following NMES, though the observable effect appeared dependent on the assessment modality used. Across tests of exercise performance, mean differences compared to control were statistically significant for the 6-minute walk, but not for the incremental shuttle walk, endurance shuttle walk, or for cardiopulmonary exercise testing with cycle ergometry. Authors concluded that NMES may be an effective treatment for muscle weakness in adults with advanced progressive disease, and could be considered as an exercise treatment for use within rehabilitation programs. Further research is very likely to have an important impact on the confidence in the estimate of effect and may change the estimate. Further research to understand the role of NMES as a component of, and in relation to, existing rehabilitation approaches is needed.

Gatewood et al. (2017) aimed to investigate the efficacy of device modalities used following arthroscopic knee surgery. Outcome measures included: muscle strength, range of motion, swelling, blood loss, pain relief, narcotic use, knee function evaluation and scores, patient satisfaction and length of hospital stay. Twenty-five studies were included in this systematic review, nineteen of which found a significant difference in outcomes. Authors concluded that NMES improve quadriceps strength and overall knee functional outcomes following knee surgery. Yue et al. (2018) assessed the evidence relative to the comparative effectiveness of neuromuscular electrical stimulation (NMES), transcutaneous electrical nerve stimulation (TENS), and electroacupuncture (EA) for improving patient rehabilitation following total knee arthroplasty (TKA). Data were analyzed from 17 randomized controlled trials involving 1285 procedures: 8 NMES studies (608 procedures), 7 TENS studies (560 procedures), and 2 EA studies (117 procedures). Qualitative analysis suggested that NMES was associated with higher quadriceps strength and functional recovery after TKA. Recovery benefits were maximal when the stimulation was performed once or twice a day for 4-6 weeks at an intensity of 100-120 mA and frequency of 30-100 Hz. The electrode should be sufficiently large (100-200 cm<sup>2</sup>) to reduce discomfort. TENS at an intensity of 15-40 mA and frequency of 70-150 Hz provided effective analgesia after TKA. EA at an intensity of 2 mA and frequency of 2 Hz may also provide postoperative analgesia of TKA. Authors concluded that as adjunct modalities, NMES and TENS can effectively improve rehabilitation after TKA without triggering significant intolerance, and maximal benefits depend on optimized parameters and intervention protocols. EA may be an effective adjunct modality for analgesia after TKA.

Novak et al. (2020) sought to provide guidelines for treatment parameters regarding electrical stimulation by investigating its efficacy in improving muscle strength and decreasing pain in patients with knee osteoarthritis. Nine randomized control trials were included in the review. First, the review confirmed that neuromuscular electrical stimulation is the most effective electrical stimulation treatment in the management of knee OA, and its efficiency is higher when combined with a strengthening program. Second, frequency of at least 50 Hz and no more than 75 Hz with a pulse duration between 200 and 400  $\mu$ s and a treatment duration of 20 mins is necessary for successful treatment. Peng et al. (2021) evaluated the effect of neuromuscular electrical stimulation (NMES) on quadriceps muscle strength, pain, and function outcomes following total knee arthroplasty (TKA). Nine RCTs that involved 691 patients were included in the meta-analysis. Pooled analysis showed that NMES improved quadriceps muscle strength after TKA within 1 month, 1-2 months, 3-4 months, and 12-13 months; pain between 1 and 2 months and between 3 and 6 months, Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) between 3 and 4 months, timed up and go test (TUG) within 1

month, 3 minute walk test between 3 and 6 months, and SF-36 MCS between 3 and 6 months after TKA. Authors concluded that as a supplementary treatment after TKA, postoperative NMES could improve the short-term to long-term quadriceps muscle strength, mid-term pain, and mid-term function following TKA. However, many outcomes failed to achieve statistically meaningful changes and minimal clinically important difference (MCID), thus the clinical benefits remained to be confirmed.

Labanca et al. (2022) investigated whether adding NMES to TKA rehabilitation leads to a better quadriceps strength recovery in comparison with standardized rehabilitation. A second aim was to investigate which are the most commonly used NMES pulse settings and their effectiveness. Intervention studies evaluating the effects of a rehabilitation intervention based on quadriceps NMES in patients undergoing TKA were retrieved. Four studies met the inclusion criteria. Due to the limited number and the heterogeneity of the selected studies, it was not appropriate to carry out a meta-analysis. All the studies reported higher quadriceps strength in patients undergoing quadriceps NMES, particularly early after TKA. The addition of NMES or traditional strength training shows similar long-term effects. Short duration and low-intensity NMES have limited effects on quadriceps strength. Heterogeneity was found on NMES methodologies and pulse settings. In conclusion, NMES is effective for quadriceps strength recovery following TKA. NMES intensity and duration are essential for good NMES outcomes on quadriceps strength. Further studies on NMES methodologies, pulse features and settings are required to address the gaps in knowledge on NMES following TKA.

Culvenor et al. (2022) synthesized the evidence for effectiveness of rehabilitation interventions following ACL and/or meniscal tear on symptomatic, functional, clinical, psychosocial, quality of life and reinjury outcomes. Authors included 22 systematic reviews (142 trials of mostly men) evaluating ACL-injured individuals and none evaluating isolated meniscal injuries. We synthesized data from 16 reviews evaluating 12 different interventions. Moderate-certainty evidence was observed for: (1) neuromuscular electrical stimulation to improve quadriceps strength; (2) open versus closed kinetic chain exercises to be similarly effective for quadriceps strength and self-reported function; (3) structured home-based versus structured in-person rehabilitation to be similarly effective for quadriceps and hamstring strength and self-reported function; and (4) postoperative knee bracing being ineffective for physical function and laxity. There was low-certainty evidence that: (1) preoperative exercise therapy improves self-reported and physical function postoperatively; (2) cryotherapy reduces pain and analgesic use; (3) psychological interventions improve anxiety/fear; and (4) whole body vibration improves quadriceps strength. There was very low-certainty evidence that: (1) protein-based supplements improve quadriceps size; (2) blood flow restriction training improves quadriceps size; (3) neuromuscular control exercises improve quadriceps and hamstring strength and self-reported function; and (4) continuous passive motion has no effect on range of motion. Authors concluded that the general level of evidence for rehabilitation after ACL or meniscal tear was low. Moderate-certainty evidence indicates that several rehabilitation types can improve quadriceps strength, while brace use has no effect on knee function/laxity.

The main goal of stroke rehabilitation is to improve function to allow patients greater independence in their activities of daily living, resulting in an improvement in quality of life. Typical treatment techniques of stroke rehabilitation comprise various combination of range of motion (ROM) and muscle strengthening exercises, mobilization activities, and compensatory techniques. Other key therapies include neurophysiological and/or developmental based methods in which the treatment program incorporates neuromuscular re-education techniques. It is in these situations that FES is used for stroke rehabilitation. It has been utilized to manage contracture of joints, maintain ROM, facilitate voluntary motor control, and reduce spasticity. However, there is insufficient evidence that FES is effective as a rehabilitative tool for patients who suffered strokes. In particular, there are little data supporting the long-term effectiveness of this modality for stroke rehabilitation and other neurologic conditions. In a Cochrane review, Price and Pandyan (2000) ascertained the effectiveness of any form of surface electric stimulation in the prevention and/or treatment of pain around the shoulder at any time after stroke. These investigators concluded that the evidence from randomized controlled studies so far does not confirm or refute that ES around the shoulder after stroke influences reports of pain, but there do appear to be benefits for passive humeral lateral rotation. A possible mechanism is through the reduction of glenohumeral subluxation. The authors stated that further studies are needed. Van Peppen et al (2004) determined the evidence for physical therapy interventions aimed at improving functional outcome after stroke. 151 studies were included in this systematic review; 123 were randomized controlled trials (RCTs) and 28 controlled clinical trials (CCTs). Researchers reported that while strong evidence was found regarding use of NMES for glenohumeral subluxation, no or insufficient evidence in terms of functional outcome was found for FES and NMES aimed at improving dexterity or gait performance. Furthermore, in a review on therapeutic orthosis and electric stimulation for upper extremity hemiplegia after stroke, Aoyagi and Tsubahara (2004) stated that despite

a number of studies suggesting the effectiveness of electrical stimulation for reducing shoulder subluxation or improving the function of wrist and finger extensors in the short term, the long term effectiveness after discontinuation as well as the motor recovery mechanism remains unclear. More research is needed to determine the evidence-based effectiveness of electrical stimulation for stroke survivors. Koyuncu et al. (2010) conducted a randomized controlled trial to evaluate FES for the treatment of 50 hemiplegic patients with shoulder subluxation and pain secondary to stroke. All patients received conventional rehabilitation and the study group also received FES stimulation to the supraspinatus and posterior deltoid muscles on the hemiplegic side, five times a day, one hour each for four weeks. Comparison of the resting AROM vs. PROM VAS value changes showed no significant difference between the groups. There was a significant difference between the two groups for the amount of change in shoulder subluxation in favor of the study group, indicating increased stability of the shoulder. Authors suggest that applying FES treatment to the supraspinatus and posterior deltoid muscles in addition to conventional treatment when treating the subluxation in hemiplegic patients is more beneficial than conventional treatment by itself. Gu and Ran (2016) reviewed the evidence for the effect of functional electrical stimulation (FES) on shoulder subluxation, pain, upper arm motor function, daily function, and quality of life in patients with stroke when added to conventional therapy. The results of this meta-analysis showed a significant difference in shoulder subluxation between the FES group and the placebo group, only if FES was applied early after stroke. And a significant difference was observed posttreatment in the Fugl-Meyer Motor Assessment between the FES group and the placebo group. No effects were found on pain, upper arm motor function, daily function, and quality of life outcomes. Authors concluded that FES can be used to prevent or reduce shoulder subluxation early after stroke. However, findings did not support the efficacy of use of FES for pain reduction, improvement in arm strength, movement, functional use, daily function, or quality of life after stroke.

FES has been proposed for improving ambulation in patients with gait disorders such as drop foot, hemiplegia due to stroke, cerebral injury, or incomplete spinal cord injury. As an example, FES can be applied to the anterior tibialis muscle to assist in dorsiflexion during gait for patients with foot drop. Several small studies support the integration of FES for patients with spinal cord injury or who have sustained a stroke for various activities. As long as the peripheral nervous system is intact, any patients with central nervous system dysfunction may benefit from FES use. Effectiveness of FES may be likely due to the direct effect of muscle strengthening in addition to increased excitability of the motor neuron pool produced by the motor level electrical stimulation (Cameron, 2017).

The Parastep I System is a FES device proposed to promote ambulation. Several publications authored by the same group of researchers in 1997 evaluated this system relative to bone density, oxygen uptake and other physiologic measures. Jacobs et al. (1997) examined the task-nonspecific effects of functional neuromuscular stimulation (FNS)-assisted ambulation training on the physiological responses of persons with paraplegia to upper extremity exercise challenge. Twelve men and three women with motor- and sensory-complete thoracic-level SCI (T4-T11), mean age 28.2 +/- 6.8yrs (range, 21.1 to 45.2yrs), mean injury duration 3.7 +/- 3.0yrs (range, 7 to 8.8yrs). Thirty-two sessions of FNS ambulation training using a commercial six-channel system (Parastep 1). This system is composed of a microprocessor-controlled electrical stimulation unit and a walking frame outfitted with finger switches that allow the user to independently control the system and stimulation parameters. Outcome measures included peak and subpeak physiological responses to arm ergometry testing and upper extremity strength measures, obtained before and after the FNS ambulation training. Statistically significant increases in peak values for time to fatigue, peak power output, and peak VO<sub>2</sub> (all  $p < .001$ ). Heart rate was significantly lower throughout subpeak levels of arm ergometry after the ambulation training ( $p < .05$ ). Values of upper extremity strength were not significantly altered after training. Authors concluded that FNS ambulation by persons with SCI paraplegia results in task-nonspecific training adaptations. Central cardiovascular adaptations were indicated as the primary source of these beneficial alterations in exercise responses.

Additionally the group provided data on ambulation and standing. Klose et al. (1997) described performance parameters and effects on anthropometric measures in spinal cord injured subjects training with the Parastep 1 system. Thirteen men and 3 women with thoracic (T4-T11) motor-complete spinal cord injury: mean age, 28.8yrs; mean duration postinjury, 3.8yrs. Thirty-two functional neuromuscular stimulation ambulation training sessions using a commercially available system (Parastep-1). The hybrid system consists of a microprocessor-controlled stimulator and a modified walking frame with finger-operated switches that permit the user to control the stimulation parameters and activate the stepping. Distance walked, time spent standing and walking, pace, circumferential (shoulders, chest, abdomen, waist, hips, upper arm, thigh, and calf) and skinfold (chest, triceps,

axilla, subscapular, supraillium, abdomen, and thigh) measurements, body weight, thigh cross-sectional area, and calculated lean tissue were outcome measures. Statistically significant changes in distance, time standing and walking, and pace were found. Increases in thigh and calf girth, thigh cross-sectional area, and calculated lean tissue, as well as a decrease in thigh skinfold measure, were all statistically significant. Authors concluded that the Parastep 1 system enables persons with thoracic-level spinal cord injuries to stand and ambulate short distances but with a high degree of performance variability across individuals. The factors that influence this variability have not been completely identified. Chaplin et al. (1996) also evaluated use of the device for ambulation. A total of 84 of 91 participants were able to take steps and of these, 31 were able to ambulate without assistance from another person. This was a case series study, which is uncontrolled and of lower methodologic quality.

Brissot et al. (2000) investigated the motor performances of use of Parastep I regarding energy expenditure and to evaluate its advantages and limitations, especially in social activities involving ambulation. This study was conducted in 15 thoracic spine-injured patients. The lesion was complete except in two patients. The gait ability and the functional use were judged clinically. Energy cost was evaluated from heart rate, peak oxygen uptake, and lactatemia. Thirteen patients completed the training (mean: 20 sessions) and achieved independent ambulation with a walker. The mean walking distance, without rest, was 52.8 +/- 69 m, and the mean speed was 0.15 +/- 0.14 m/sec. One patient with incomplete lesion, who had been nonambulatory for 8 months after the injury, became able to walk without functional electrical stimulation after five sessions. The follow-up was 40 +/- 11 months. Five patients pursued using functional electrical stimulation-assisted gait as a means of physical exercise but not for ambulation in social activities. The patients experienced marked psychological benefits, with positive changes in their way of life. In three subjects, a comparison of physiologic responses to exercise between a progressive arm ergometer test and a walking test with the Parastep (Sigmedics, Inc., Northfield, IL) at a speed of 0.1 m/sec was performed, showing that the heart rate, the peak oxygen uptake, and lactatemia during gait were close to those obtained at the end of the maximal test on the ergometer. Authors concluded that in spite of its ease of operation and good cosmetic acceptance, the Parastep approach has very limited applications for mobility in daily life, because of its modest performance associated with high metabolic cost and cardiovascular strain. However, it can be proposed as a resource to keep physical and psychological fitness in patients with spinal cord injury.

Morawietz and Moffat (2013) provided an overview of, and evaluate the current evidence on, locomotor training approaches for gait rehabilitation in individuals with incomplete spinal cord injury to identify the most effective therapies. Only randomized controlled trials evaluating locomotor therapies after incomplete spinal cord injury in an adult population were included. Eight articles were included in this review. Five compared body-weight-supported treadmill training (BWSTT) or robotic-assisted BWSTT with conventional gait training in acute/subacute subjects ( $\leq 1$  y postinjury). The remaining studies each compared 3 or 4 different locomotor interventions in chronic participants ( $> 1$  y postinjury). Sample sizes were small, and study designs differed considerably impeding comparison. Only minor differences in outcomes measures were found between groups. Gait parameters improved slightly more after BWSTT and robotic gait training for acute participants. For chronic participants, improvements were greater after BWSTT with functional electrical stimulation and overground training with functional electrical stimulation/body-weight support compared with BWSTT with manual assistance, robotic gait training, or conventional physiotherapy. Authors concluded that evidence on the effectiveness of locomotor therapy is limited. All approaches show some potential for improvement of ambulatory function without superiority of 1 approach over another. More research on this topic is required.

Yan and colleagues (2005) evaluated whether FES was more effective in promoting motor recovery of the lower extremity and walking ability than standard rehabilitation alone. A total of 46 patients were assigned randomly to one of three groups receiving standard rehabilitation with FES or placebo stimulation or alone (control). They received treatment for 3 weeks, starting shortly after having the stroke. Outcome measurements included composite spasticity score, maximum isometric voluntary contraction of ankle dorsi-flexors and planter-flexors, and walking ability. After 3 weeks of treatment, those receiving FES plus standard rehabilitation did better on several measures of lower limb functioning compared to the other 2 groups. All patients in the FES group were able to walk after treatment, and 84.6 % of them returned home, in comparison with the placebo (53.3 %) and control (46.2 %) groups. However, these authors stated that generalization of the results from this study should be performed with caution because of subject selection criteria, which did not cover all stroke categories or subjects aged younger than 45 or older than 85 years. Randomized controlled trials and case series have primarily included small patient populations (n=14-64) with short-term follow-ups and heterogeneous treatment

regimens and outcome measures (Esnour, et al., 2010; Nooijen, et al., 2009; Everaert, et al., 2010; Stein, et al., 2010; Barrett, et al., 2010; Postans, et al., 2004).

In a Cochrane review on electrostimulation for promoting recovery of movement or functional ability after stroke, Pomeroy et al (2006) sought to find out whether electrostimulation improved functional motor ability to do activities of daily living. Twenty-four trials were included in the review. Authors reported that electrostimulation improved some aspects of functional motor ability and some aspects of motor impairment and normality of movement over no treatment. For electrostimulation compared with placebo, this review found that electrostimulation improved an aspect of functional motor ability. For electrostimulation compared with conventional physical therapy, they found that electrostimulation improved an aspect of motor impairment. There were no statistically significant differences between electrostimulation and control treatment for all other outcomes. Authors caution that these results need to be interpreted with reference to the following: (1) the majority of analyses only contained one trial; (2) variation was found between included trials in time after stroke, level of functional deficit, and dose of electrostimulation; and (3) the possibility of selection and detection bias in the majority of included trials. Researchers conclude that data were insufficient to inform clinical use of electrostimulation for neuromuscular re-training. Research is needed to address specific questions about the type of electrostimulation that might be most effective, in what dose and at what time after stroke. Pereira et al. (2012) conducted a systematic review of randomized controlled trials to evaluate the effectiveness of FES in improving lower limb function in chronic stroke patients (mean time since stroke  $\geq 6$  mos). Seven RCTs including a pooled sample size of 231 participants met inclusion criteria. Analysis revealed a small but significant treatment effect in favor of FES on the 6 minute walk test. Authors conclude that FES may be an effective intervention in the chronic phase post stroke. However, its therapeutic value in improving lower extremity function and advantage over other gait training approaches remains uncertain.

Howlett et al. (2015) conducted a systematic review and meta-analysis to investigate the effectiveness of FES in improving activity following a stroke and to determine if FES is more effective than training alone. Eighteen randomized and non-randomized comparisons studies ( $n=485$ ) met inclusion criteria. One study had three arms which was counted as a separate comparison group ( $n=19$  comparisons). Because of incomplete data, all trials were not included in the meta-analysis. Only measures that reflected the International Classification of Function domain of activity performance were used in analyses. In some trials only one measure was available and in trials with more than one measure the reviewers chose the measure that most closely reflected the task being trained. Various outcome measures were used for lower-limb and upper-limb activity assessments. FES had a small to moderate effect on activity compared to no FES or placebo and had a moderate effect on activity compared to training alone. However, due to the lack of available data, the authors were unable determine if FES improved subject participation or if the benefits of FES are long-term. Author-noted limitations of the studies included: the lack of blinding of therapist and participants; the potential of small trial bias with 25 being the average number of participants per trial; and combining data for the meta-analysis that was collected using different outcome measures. There was also heterogeneity of subject characteristics including time after stroke, the limb that was trained, and the severity of stroke. In a randomized controlled study, Bethoux et al. (2015) compared changes in gait quality and function between FES and ankle-foot orthoses (AFOs) in individuals with foot drop post-stroke over a 12 month period. They completed a follow-up analysis on a multi-center unblinded RCT that had been conducted at 30 rehabilitation centers. Subjects continued to wear their randomized device for all home and community ambulation for another 6 months to final 12-month assessments. Primary outcomes were the 10 Meter Walk Test (10MWT) and device-related serious adverse event rate. Secondary outcome measures were the 6-Minute Walk Test (6MWT), GaitRite Functional Ambulation Profile, and the Modified Emory Functional Ambulation Profile (mEFAP). A total of 495 subjects were randomized, and 384 completed the 12-month follow-up. Both FES and AFO groups showed statistically and clinically significant improvement for 10MWT. No significant between group differences were found. At 12 months, both FES and AFOs continue to demonstrate equivalent gains in gait speed. Results suggest that long-term FES use may lead to additional improvements in walking endurance and functional ambulation; further research is needed to confirm these findings.

Prenton et al. (2016) conducted a systematic review and meta-analysis of randomized controlled trials to compare the effects of FES and ankle foot orthoses (AFO) for foot drop of central neurological origin. Five synthesized randomized controlled trials ( $n=815$ ) were included. Orthotics included customized and off the shelf AFOs. Meta-analysis of the outcomes of the 10-meter (m) walking speed (5 trials) ( $n=789$ ) and functional exercise capacity (3 trials) ( $n=761$ ) showed between group comparable improvements which were not significant ( $p=0.79$ ;  $p=0.31$ , respectively). There were no significant differences in meta-analysis for the 10-meter (m) walk

test using data at short- (4 trials; n=771) and longer-term (3 trials; n=713) time-points for FES vs. AFO. There was a significant difference ( $p=0.04$ ) in favor of the AFO for the medium-term 10-m test. Analyses revealed between group comparable improvements in functional exercise capacity. The timed up-and-go test was reported in two studies and both reported between-group comparable improvements ( $p=0.812$  and  $p=0.539$ ). The mobility domain of the Stroke Impact Scale (SIS) was reported by three trials (n=701) and showed comparable between-group improvements ( $p=0.80$ ). This meta-analysis indicates that AFOs have positive combined-orthotic effects on walking that are equivalent to FES for foot-drop caused by stroke regardless of length of use. The fact that the reviewed trials only included subjects age 18 years and older who had experienced a stroke prevents the results from being generalized to other populations. Other limitations of the analysis included the risk of bias in the studies and the heterogeneity of the AFO and FES devices used.

Stein et al. (2015) conducted a systematic review (n=29 studies; 940 subjects) and meta-analysis (n=14 studies; 383 subjects) of randomized controlled trials to evaluate the effect of NMES on spastic muscles after stroke. The primary outcome was spasticity, assessed by the Modified Ashworth Scale. The secondary outcome was range of motion (n=13 studies), assessed by a goniometer. Outcomes were conflicting. Some studies reported an improvement in spasticity (n=12 studies) and range of motion (n=13 studies) with NMES when used as an adjunctive therapy and some studies did not. Based on sensitivity analysis, no effects on spasticity and range of motion were seen on wrists and no effect on spasticity of elbows. The degree of spasticity and the criteria for spasticity assessment varied. Most studies showed evidence of bias. Other study limitations included: heterogeneity of outcome measures; time of treatment following stroke (1.5 months to more than 12 months); various degrees of chronic tissue changes; heterogeneity of conventional therapies used (e.g., active leg cycling, occupational therapy, stretching, Botulinum Toxin A), missing data; and heterogeneity of stimulation frequency and pulse duration. Large scale and high-quality randomized controlled trials are needed to establish the true efficacy NMES in this patient population. Sharififar et al. (2018) aimed to determine the effect on motor function of extremities of adding an electrical sensory modality without motor recruitment before or with routine rehabilitation for hemiparesis after stroke by a comprehensive systematic review and meta-analysis. Authors concluded that electrical sensory input can contribute to routine rehabilitation to improve early post-stroke lower-extremity impairment and late motor function, with no change in spasticity. Prolonged periods of sensory stimulation such as TENS combined with activity can have beneficial effects on impairment and function after stroke.

Kristensen et al. (2021) sought to determine the effectiveness of neuromuscular electrical stimulation (NMES) toward improving activities of daily living (ADL) and functional motor ability post stroke and to investigate the influence of paresis severity and the timing of treatment initiation for the effectiveness of NMES. The inclusion criteria were randomized controlled trials exploring the effect of NMES toward improving ADL or functional motor ability in survivors of stroke. The search identified 6064 potential articles with 20 being included. Data from 428 and 659 participants (mean age, 62.4 years; 54% male) for outcomes of ADL and functional motor ability, respectively, were pooled in a random-effect meta-analysis. The analysis revealed a significant positive effect of NMES toward ADL, whereas no effect on functional motor ability was evident. Subgroup analyses showed that application of NMES in the subacute stage and in the upper extremity improved ADL, whereas a beneficial effect was observed for functional motor abilities in patients with severe paresis. Authors concluded that the results of the present meta-analysis are indicative of potential beneficial effects of NMES toward improving ADL post stroke, whereas the potential for improving functional motor ability appears less clear. Furthermore, subgroup analyses indicated that NMES application in the subacute stage and targeted at the upper extremity is efficacious for ADL rehabilitation and that functional motor abilities can be positively affected in patients with severe paresis.

Johnston et al. (2021) provided evidence to guide clinical decision-making for the use of either ankle-foot orthosis (AFO) or functional electrical stimulation (FES) as an intervention to improve body function and structure, activity, and participation as defined by the International Classification of Functioning, Disability and Health (ICF) for individuals with poststroke hemiplegia with decreased lower extremity motor control within this clinical practice guideline. A review of literature published through November 2019 was performed across 7 databases for all studies involving stroke and AFO or FES. Data extracted included time post-stroke, participant characteristics, device types, outcomes assessed, and intervention parameters. Outcomes were examined upon initial application and after training. Recommendations were determined on the basis of the strength of the evidence and the potential benefits, harm, risks, or costs of providing AFO or FES. One-hundred twenty-two meta-analyses, systematic reviews, randomized controlled trials, and cohort studies were included. Strong evidence exists that AFO and FES can each increase gait speed, mobility, and dynamic balance. Moderate

evidence exists that AFO and FES increase quality of life, walking endurance, and muscle activation, and weak evidence exists for improving gait kinematics. AFO or FES should not be used to decrease plantarflexor spasticity. Studies that directly compare AFO and FES do not indicate overall superiority of one over the other. But evidence suggests that AFO may lead to more compensatory effects while FES may lead to more therapeutic effects. Due to the potential for gains at any phase post-stroke, the most appropriate device for an individual may change, and reassessments should be completed to ensure the device is meeting the individual's needs. It is important to note that this CPG cannot address the effects of one type of AFO over another for the majority of outcomes, as studies used a variety of AFO types and rarely differentiated effects. The recommendations also do not address the severity of hemiparesis, and most studies included participants with varied baseline ambulation ability. Authors summarize that this CPG suggests that AFO and FES both lead to improvements post-stroke. Future studies should examine timing of provision, device types, intervention duration and delivery, longer term follow-up, responders versus nonresponders, and individuals with greater impairments.

van der Scheer et al. (2021) summarized and appraise evidence on functional electrical stimulation (FES) cycling exercise after spinal cord injury (SCI), in order to inform the development of evidence-based clinical practice guidelines. Ninety-two studies met the eligibility criteria, comprising 999 adults with SCI representing all age, sex, time since injury, lesion level and lesion completeness strata. For muscle health (e.g., muscle mass, fiber type composition), significant improvements were found in 3 out of 4 Level 1-2 studies, and 27 out of 32 Level 3-4 studies (GRADE rating: 'High'). Although lacking Level 1-2 studies, significant improvements were also found in nearly all of 35 Level 3-4 studies on power output and aerobic fitness (e.g., peak power and oxygen uptake during an FES cycling test) (GRADE ratings: 'Low'). Authors concluded that the evidence indicates that FES cycling exercise improves lower-body muscle health of adults with SCI and may increase power output and aerobic fitness. Mahmoudi et al. (2021) systematically reviewed the effect of functional electrical stimulation (FES) on balance as compared to conventional therapy alone in post-stroke. Nine papers were included in this review. The total number of participants in this review study was 255. The age of participants ranged from 20 to 80 years. Stroke patients were in chronic phase ( $n = 5$ ) and in subacute phase ( $n = 4$ ). Various parameters, including the target muscles, the treatment time per session (20 min-2 h), number of treatment sessions (12-48) and FES frequency (25-40 Hz), were assessed. Among the studies, significant between-group improvement favoring FES in combination with conventional therapy was found on the Berg Balance Scale ( $n = 7$ ) and Timed Up and Go Scale ( $n = 4$ ) when compared to conventional therapy alone. There was no adverse effect reported by any studies. Authors concluded that FES was reported to be more beneficial in balance improvement among stroke patients when combined with conventional balance therapy. The studies were limited by low-powered, small sample sizes ranging from 9 to 48, and lack of blinding, and reporting of missing data.

Electrical stimulation has been employed as a safe and effective therapy for improving arm function after stroke. Contralaterally controlled functional electrical stimulation (CCFES) is a unique method that has progressed from application in small feasibility studies to implementation in several randomized controlled trials. However, no meta-analysis has been conducted to summarize its efficacy. Loh et al. (2022) summarized the effect size of CCFES through measures of upper extremity motor recovery compared with that of neuromuscular electrical stimulation (NMES). Six RCTs were selected and 267 participants were included. The Upper Extremity Fugl-Meyer assessment (UEFMA) was included in all studies, the Box and Blocks test (BBT) and active range of motion (AROM) were included in 3 and 4 studies, respectively. The modified Barthel Index (mBI) and Arm Motor Abilities Test (AMAT) were included in 2 and 3 studies, respectively. The CCFES group demonstrated greater improvement than the NMES did in UEFMA, AROM, and mBI. However, the results for AMAT did not differ significantly. Authors concluded that contralaterally controlled functional electrical stimulation produced greater improvements in upper extremity hemiplegia in people with stroke than NMES did.

Ye et al. (2021) comprehensively and critically appraised the clinical benefits and engineering designs of functional electrical stimulation (FES)-rowing for management of individuals with spinal cord injury (SCI). Comparison of peak oxygen consumption ( $\text{Vo}_{2\text{peak}}$ ) rates showed that  $\text{Vo}_{2\text{peak}}$  during FES-rowing was significantly higher than arm-only exercise; FES-rowing training improved  $\text{Vo}_{2\text{peak}}$  by 11.2% on average, with a 4.1% increase in  $\text{Vo}_{2\text{peak}}$  per month of training. FES-rowing training reduced bone density loss with increased time postinjury. The rowing ergometer used in 2 studies provided motor assistance during rowing. Studies preferred manual stimulation control ( $n=20$ ) over automatic ( $n=4$ ). Authors concluded that results suggest FES-rowing is a viable exercise for individuals with SCI that can improve cardiovascular performance and reduce bone density loss. Further randomized controlled trials are needed to better understand the optimal set-up for

FES-rowing that maximizes the rehabilitation outcomes. Karamian et al. (2022) summarized the various forms of electrical stimulation technology that exist and their applications for SCI. With regards to FES and NMES, authors report positive findings for improvement in muscle function and functional activities.

Chiu et al. (2014) conducted a systematic review to determine the effectiveness of FES vs. activity training alone in children with cerebral palsy. Five randomized controlled trials met inclusion criteria. The experimental group had to receive FES while performing an activity such as walking. The studies used outcome measures of activity that best reflected the activity used in the study. When continuous data (e.g., walking speed) were not available, ordinal data (e.g., Gross Motor Function Measurement) were used. A statistically significant between-group difference in activity in the FES groups was reported for the three studies that compared FES with no FES. Improvements were seen immediately after the intervention period, but long-term follow-up was not reported. The two studies investigating the effects of FES vs. activity training reported no significant differences between the groups. The results reported that FES is better than no FES but that FES is not more effective than activity training. Outcomes could not be pooled for meta-analysis due to incomplete data and the large difference in baseline scores. Due to the inability to conduct a meta-analysis, the authors stated that firm conclusions could not be made. Limitations of the studies included the heterogeneous patient populations and the variations in the frequency, intensity and duration of the interventions. Bosques et al. (2016) discussed the potential clinical applicability, while clarifying the differences in electrical stimulation (ES) treatments and the theory behind potential benefits to remediate functional impairments in youth in a comprehensive review. The synthesis of the literature suggests that improvements in various impairments may be possible with the integration of ES. Most studies were completed on children with cerebral palsy (CP). Electrical stimulation may improve muscle mass and strength, spasticity, passive range of motion (PROM), upper extremity function, walking speed, and positioning of the foot and ankle kinematics during walking. Sitting posture and static/dynamic sitting balance may be improved with ES to trunk musculature. Bone mineral density may be positively affected with the use of Functional Electrical Stimulation (FES) ergometry. ES may also be useful in the management of urinary tract dysfunction and chronic constipation. Among all reviewed studies, reports of direct adverse reactions to electrical stimulation were rare. In conclusion, NMES and FES appear to be safe and well tolerated in children with various disabilities. Authors suggested that physiatrists and other healthcare providers better understand the indications and parameters in order to utilize these tools effectively in the pediatric population.

Springer and Khamis (2017) completed a systematic review on the orthotic and therapeutic effects of functional electrical stimulation on gait in people with multiple sclerosis (MS). Twelve relevant studies were reviewed. Eleven studies reported the effects of peroneal stimulation. Most found a significant orthotic effect (measured during stimulation), mainly on walking speed. Only three assessed the therapeutic effect (carry-over), which was not significant. Authors concluded that the evidence suggests that FES has a positive orthotic effect on walking in patients with MS. Yet, more robust trials are needed to substantiate this finding. Therapeutic efficacy of FES was not demonstrated.

Ou et al. (2022) assessed the effects of neuromuscular electrical stimulation on the upper limbs of patients with cerebral palsy. Eight randomized controlled trials (N = 294) were included in the meta-analysis. Compared with traditional physical therapy, sensorimotor training and task-oriented training, constraint-induced movement therapy, dynamic bracing, and conventional robot-assisted therapy, neuromuscular electrical stimulation in combination with these therapies resulted in significantly greater functional scale scores, muscle strength of upper limbs, and spasticity of upper limbs but did not improve the wrist range of motion. In addition, the effect of neuromuscular electrical stimulation on functional scale scores remained after 3-mo follow-up. Authors concluded that neuromuscular electrical stimulation effectively improved hand function, muscle strength, and spasticity in patients with cerebral palsy.

Zhu et al. (2022) summarized and analyzed the relationship between functional electrical stimulation treatment and gait parameter changes in children with cerebral palsy. Nine papers were included in the analysis, with a total of 282 children with cerebral palsy, including 142 patients in the functional electrical stimulation treatment group and 140 patients in the comfort treatment, general nursing, or other physical therapy. The results showed that functional electrical stimulation could increase the walking speed of children with cerebral palsy and increase the walking step length of children with cerebral palsy. Authors concluded that functional nerve stimulation treatment could increase the gait speed and step length of children with cerebral palsy, which could improve the walking of children with cerebral palsy. Furthermore, this study needs more research data to support our findings.

Electrical stimulation (ES) has been examined for the treatment of dysphagia. However, there is currently insufficient evidence to support the effectiveness of ES in treating this condition. No peer-reviewed literature was found for DPNS specifically, but rather is limited to electrical stimulation, FES, or NMES. In a non-concurrent cohort study, Blumenfeld et al. (2006) assessed the effectiveness of ES in treating persons with dysphagia and aspiration. The charts of 40 consecutive subjects undergoing ES and 40 consecutive persons undergoing traditional dysphagia therapy (TDT) were reviewed. The swallow severity scale improved from 0.50 to 1.48 in the TDT group ( $p < 0.05$ ) and from 0.28 to 3.23 in the ES group ( $p < 0.001$ ). After adjusting for potential confounding factors, persons receiving ES did significantly better in regard to improvement in their swallowing function than persons receiving TDT ( $p = 0.003$ ). The authors concluded that the findings suggested that dysphagia therapy with transcutaneous ES is superior to traditional dysphagia therapy alone in individuals in a long-term acute care facility. They also stated that confirmation of these findings with a prospective, placebo-controlled, randomized clinical trial is needed before a definitive determination regarding the effectiveness of ES dysphagia therapy can be made. Kiger et al. (2006) compared the outcomes using transcutaneous neuromuscular electrical stimulation (VitalStim® therapy) to outcomes using traditional swallowing therapy for deglutition disorders. A total of 22 patients had an initial and a follow-up video-fluoroscopic swallowing study or fiberoptic endoscopic evaluation of swallowing and were divided into an experimental group that received VitalStim® treatments and a control group that received traditional swallowing therapy. Outcomes were analyzed for changes in oral and pharyngeal phase dysphagia severity, dietary consistency restrictions, and progression from non-oral to oral intake. Results of chi-square analysis showed no statistically significant difference in outcomes between the experimental and control groups.

Huckabee and Doeltgen (2007) reviewed NMES as an emerging modality in an attempt to advise the New Zealand medical community about the application of it as a treatment for pharyngeal swallowing impairment (dysphagia). Authors conclude that there are potential benefits of the use of this treatment but key concerns for patient safety and long term outcomes exist. Shaw et al. (2007) sought to evaluate the effectiveness of VitalStim® therapy in a heterogeneous group of dysphagic patients. They performed a retrospective analysis of 18 patients who received this therapy at an urban tertiary referral center. All patients underwent pre-therapy evaluation by speech-language pathologists, including modified barium swallow and/or functional endoscopic evaluation of swallowing and clinical evaluation of swallowing that included assessment of laryngeal elevation, diet tolerance, and swallowing delay, and were then assigned an overall dysphagia severity score. After therapy, all patients underwent the same assessments. Twelve of the 18 also underwent a functional swallowing telephone survey months (range, 1 to 21 months) after their therapy to assess whether the improvement was worthwhile and sustained. Eleven of the 18 patients (61%) demonstrated some improvement in their swallowing. Six of the 18 patients (33%) were improved enough to no longer require a feeding tube. However, of the 5 patients categorized as having "severe dysphagia" before therapy, only 2 showed any improvement, and these patients still required a feeding tube for adequate nutrition. Telephone surveys did confirm that those who improved with their therapy seemed to maintain their progress and that most patients were satisfied with their therapy. Authors concluded that VitalStim therapy seems to help those with mild to moderate dysphagia. However, the patients with the most severe dysphagia in the study did not gain independence from their feeding tubes but could potential help those with mild to moderate dysphagia. Carnaby-Mann and Crary (2007) examined the evidence on neuromuscular electrical stimulation for swallowing rehabilitation. A total of 81 studies were reviewed. Seven were accepted for analysis. A significant summary effect size was identified for the application of NMES for swallowing. Best-evidence synthesis showed indicative findings in favor of NMES for swallowing. The analysis revealed a small but significant summary effect size for NMES for swallowing. Because of the small number of studies and low methodological grading for these studies, caution should be taken in interpreting this finding. These results support the need for more rigorous research in this area. This is in agreement with the observation of Steel et al (2007) who noted that although ES approaches to the restoration and rehabilitation of swallowing is an exciting area of research which holds promise for future clinically relevant technology and/or therapy, implementation of ES in clinical swallowing rehabilitation settings still remains pre-mature.

Clark et al. (2009) systematically reviewed the literature examining the effects of NMES on swallowing and neural activation. The review was conducted as part of a series examining the effects of oral motor exercises (OMEs) on speech, swallowing, and neural activation. Out of 899 citations initially identified for the broad review of OMEs, 14 articles relating to NMES qualified for inclusion. Most of the studies (10/14) were considered exploratory research, and many had significant methodological limitations. Authors concluded that the review revealed that surface NMES to the neck has been most extensively studied with promising findings, yet high-

quality controlled trials are needed to provide evidence of efficacy. Surface NMES to the palate, faucial pillars, and pharynx has been explored in Phase I research, but no evidence of efficacy is currently available. Intramuscular NMES has been investigated in a single Phase I exploratory study. Additional research is needed to document the effects of such protocols on swallowing performance. Christiaanse et al. (2011) compared the change in swallowing function in pediatric patients with dysphagia who received neuromuscular electrical stimulation (NMES) to a control group who received usual oral motor training and dietary manipulations without NMES. Children were classified into two groups based on the etiology of their dysphagia (primary vs. acquired). Only the treatment group who had acquired dysphagia improved more than the similar subgroup of control children. Authors concluded that NMES treatment of anterior neck muscles in a heterogeneous group of pediatric patients with dysphagia did not improve the swallow function more than that seen in patients who did not receive NMES treatment. However, there may be subgroups of children that will improve with NMES treatment. Geeganage et al. (2012) assessed the effectiveness of interventions for the treatment of dysphagia and nutritional and fluid supplementation in patients with acute and subacute stroke. Authors included 33 studies involving 6779 participants. Swallowing therapies included the following: acupuncture, drug therapy, neuromuscular electrical stimulation, pharyngeal electrical stimulation, physical stimulation (thermal, tactile), transcranial direct current stimulation, and transcranial magnetic stimulation. Authors conclude that there remains insufficient data on the effect of swallowing therapy, feeding, and nutritional and fluid supplementation on functional outcome and death in dysphagic patients with acute or subacute stroke. Behavioural interventions and acupuncture reduced dysphagia, and pharyngeal electrical stimulation reduced pharyngeal transit time.

Tan et al. (2013) assessed the overall efficacy by comparing the two treatment protocols in a meta-analysis. Studies that compared the efficacy of treatment and clinical outcomes of NMES versus traditional treatment (TT) in dysphagia rehabilitation were assessed. Seven studies were eligible for inclusion, including 291 patients, 175 of whom received NMES and 116 of whom received TT. Of the seven studies, there were two randomized controlled trials, one multicentre randomized controlled trial and four clinical controlled trials. The change scores on the Swallowing Function Scale of patients with dysphagia treated with NMES were significantly higher compared with patients treated with TT. However, subgroup analysis according to etiology showed that there were no differences between NMES and TT in dysphagia post-stroke. No studies reported complications of NMES. Authors concluded that NMES is more effective for treatment of adult dysphagia patients of variable etiologies than TT. However, in patients with dysphagia post-stroke, the effectiveness was comparable. Miller et al (2014) performed a systematic review of the literature on the use of neuromuscular electrostimulation (NMES) in otorhinolaryngology that have been published in German or English. The search identified 180 studies. These were evaluated and relevant studies were included in the further evaluation. The authors concluded that the evidence collected to date is encouraging; particularly for the treatment of certain forms of dysphagia and laryngeal paresis. Terré and Mearin (2015) evaluated the effectiveness of neuromuscular electrical stimulation (NMES) treatment in patients with oropharyngeal dysphagia secondary to acquired brain injury. Twenty patients with neurological oropharyngeal dysphagia (14 stroke and six severe traumatic brain injury) were enrolled in a prospective randomized study, with patients and assessors blinded (to group allocation): 10 patients underwent NMES and conventional swallowing therapy and 10 patients underwent sham electrical stimulation (SES) and conventional swallowing therapy. Both groups completed 20 sessions. Feeding swallowing capacity was evaluated using the functional oral intake scale (FOIS). After treatment, the NMES group increased by 2.6 points (4.5 points) compared with only 1 point (3.1 points) for the SES group. At 3 months of follow-up, mean scores were 5.3 and 4.6 respectively; thus, both groups improved similarly. At that time point (3 months), tracheal aspiration persisted in six patients in each group. However, a significant improvement in relation to the bolus viscosity at which aspiration appeared was found in the NMES group versus the SES group. Also, a significant increase in pharyngeal amplitude contraction was observed at the end of treatment (1 month) in the NMES group compared with the SES group. Authors concluded that NMES significantly accelerated swallowing function improvement in patients with oropharyngeal dysphagia secondary to acquired brain injury. Chen et al. (2016) evaluated whether swallow treatment with neuromuscular electrical stimulation is superior to that without neuromuscular electrical stimulation, and whether neuromuscular electrical stimulation alone is superior to swallow therapy. Eight studies were identified. Authors concluded that swallow treatment with neuromuscular electrical stimulation seems to be more effective than that without neuromuscular electrical stimulation for post-stroke dysphagia in the short term considering the limited number of studies available. Evidence was insufficient to indicate that neuromuscular electrical stimulation alone was superior to swallow therapy. Alamer et al. (2020) summarized the latest best scientific evidence on the efficacy of neuromuscular electrical stimulation on swallowing function in dysphagic stroke patients. Evidence of overall quality was graded from moderate to high. Eleven RCTs involving 784 patients were analyzed. The primary outcome measures of this review were functional dysphagia scale (FDS) and standard swallowing assessment. This review found neuromuscular

electrical stimulation (NMES) coupled with traditional swallowing therapy could be an optional intervention to improve swallowing function after stroke in rehabilitation department.

Liang et al. (2021) explored the clinical efficacy of VitalStim electrical stimulation combined with swallowing function training for patients with dysphagia following an acute stroke. Seventy-two patients with dysphagia following an acute stroke were admitted to our hospital and were further divided into two groups using prospective research methods. There were 36 cases in each group according to the random number table method. The control group received conventional medical treatment and swallowing function training while the experimental group received conventional medical treatment and VitalStim electrical stimulation combined with swallowing function training. The overall response rate of the experimental group (94.44%) was higher than that of the control group (77.78%), and the difference was statistically significant. Compared with before treatment, the upward and forward movement speeds of the hyoid bone, anterior movement speed, the grading score of the Kubota drinking water test, Caiteng's grading score, serum superoxide dismutase, 5-hydroxytryptamine, and norepinephrine levels, Fugl-Meyer Assessment score, and multiple quality of life scores of the two groups showed improvement after treatment. While the standard swallowing assessment score, serum malondialdehyde level, and National Institutes of Health Stroke Scale score decreased, the aforementioned indices showed a significant improvement in the experimental group. Authors concluded that the results of this study indicate that VitalStim electrical stimulation combined with swallowing function is effective for treating dysphagia following an acute stroke. It can effectively improve swallowing, neurological, and limb motor functions, reduce complications, promote physical recovery, and improve overall quality of life of patients.

Propp et al. (2022) aimed to determine the effectiveness of neuromuscular electrical stimulation (NMES) for treatment of oropharyngeal dysphagia in children. Studies of children ( $\leq 18$  years) diagnosed with oropharyngeal dysphagia using NMES in the throat/neck region were included. A meta-analysis was not conducted due to clinical heterogeneity in studies. Ten studies were included (5 RCTs, 4 case series, 1 cohort study; including 393 children, mean or median age below 7 years, including children with neurologic impairments). In all studies, swallowing function improved after NMES treatment. Eight of 10 studies reported on the child's feeding ability, and, with one exception, there was improvement in feeding ability. The studies demonstrated moderate to high risk of bias. Authors concluded that NMES treatment may be beneficial in improving swallowing function for children with dysphagia, however, given the quality of the studies, inadequate outcome reporting, and short follow-up duration, uncertainty remains. Well-designed RCTs are needed to establish its effectiveness before its adoption in clinical practice.

Miller et al. (2022) evaluated recent studies regarding a potential effectiveness of transcutaneous NMES applied to the anterior neck as a treatment for dysphagia. Eighteen studies were identified with varying patient groups, stimulation protocols, electrode placement and therapy settings. However, 16 studies have reported of beneficial outcomes in relation with NMES. It could generally be concluded that there is a considerable amount of level 2 studies which suggest that NMES is an effective treatment option, especially when combined with traditional dysphagia therapy for patients with dysphagia after stroke and patients with Parkinson's disease, or with different kinds of brain injuries. Further research is still necessary in order to clarify which stimulation protocols, parameters and therapy settings are most beneficial for certain patient groups and degrees of impairment.

Literature does not support the use of NMES for the treatment of heart failure. (Arena et al., 2010) conducted a systematic review of the literature to evaluate the evidence supporting NMES and inspiratory muscle training (IMT) for the treatment of systolic heart failure. Thirteen NMES studies met inclusion criteria, ten were randomized controlled trials. Although the studies reported improvement in aerobic capacity, peak oxygen uptake and strength and endurance of muscle groups, the studies were limited by patient population (i.e., mostly males), diverse NMES training protocols, variation in the type of muscle contraction elicited (i.e., titanic vs. twitch), the use of different muscle groups and different comparators. The percent improvement in peak oxygen uptake was consistently greater with conventional therapy (i.e., bicycle/treadmill). Sillen et al. (2009) conducted a systematic review of randomized controlled trials to analyze the role of NMES in strength, exercise capacity, and disease-specific health status in patients with congestive heart failure ( $n=9$  studies) and chronic obstructive pulmonary disease ( $n=5$  studies) with disabling dyspnea, fatigue, and exercise intolerance. The limited number of studies, heterogeneous patient populations and variability in NMES methodology prohibited the use of meta-analysis. Although some of the studies reported significant improvements with NMES compared to no exercise or usual care, outcomes, including adverse events, were conflicting. Additional studies are indicated to provide sufficient evidence to establish the clinical utility of NMES in this patient population.

### **Pelvic Floor Stimulation (electric or electromagnetic)**

Stewart et al. (2017) assessed the effects of electrical stimulation with non-implanted devices, alone or in combination with other treatment, for managing stress urinary incontinence or stress-predominant mixed urinary incontinence in women. Eligible trials (n=56) included adult women with SUI or stress-predominant mixed urinary incontinence (MUI). Authors concluded that electrical stimulation (ES) probably improves incontinence-specific quality of life (QoL) compared to no treatment but there may be little or no difference between electrical stimulation and pelvic floor muscle training (PFMT). Consistent with other reviews, it is uncertain whether adding electrical stimulation to PFMT makes any difference in terms of quality of life, compared with PFMT alone. The impact of electrical stimulation on subjective cure/improvement and incontinence-specific QoL, compared with vaginal cones, PFMT plus vaginal cones, or drug therapy, is uncertain. Comparisons of different types of ES to each other and of ES plus surgery to surgery are also inconclusive in terms of subjective cure/improvement and incontinence-specific QoL. Authors concluded that the current evidence base indicated that electrical stimulation is probably more effective than no active or sham treatment, but it is not possible to say whether ES is similar to PFMT or other active treatments in effectiveness or not. Overall, the quality of the evidence was too low to provide reliable results. Pan et al. (2018) evaluated the value of magnetic stimulation (MS) in patients with pelvic floor dysfunction (PFD). A total of 20 studies including 1019 patients were eligible for inclusion whose level of evidence for the included studies was low. Meta-analysis of four trials comparing MS with sham intervention showed that MS was not associated with significant improvement in outcomes or QoL, or number of leakages. Narrative review showed that there were no convincing evidences that MS was effective for chronic pelvic floor pain, detrusor overactivity, or overactive bladder. Authors concluded that there is no convincing evidence to support the benefits of using MS in the management of PFD. The applicability of MS in the treatment of PFD remains uncertain, so larger, well-designed trials with longer follow-up periods adopted relevant and comparable outcomes are needed to be further explored to provide a definitive conclusion.

Ignácio et al. (2022) sought to determine what the effect is of an intravaginal electrical stimulation regimen on their ability to contract the pelvic floor muscles and on self-reported urinary incontinence in women who are unable to contract their pelvic floor muscles voluntarily. Sixty-four women with pelvic floor muscle function assessed by bi-digital palpation to be grade 0 or 1 on the Modified Oxford Scale. For 8 weeks, participants randomised to the experimental group received weekly 20-minute sessions of intravaginal electrical stimulation with instructions to attempt pelvic floor muscle contractions during the bursts of electrical stimulation in the final 10 minutes of each session. The control group received no intervention. The primary outcome was ability to voluntarily contract the pelvic floor muscles, evaluated through vaginal palpation using the Modified Oxford Scale. Secondary outcomes were prevalence and severity of urinary incontinence symptoms assessed by the International Consultation on Incontinence Questionnaire on Urinary Incontinence-Short Form (ICIQ-UI-SF) score from 0 to 21. Sixty-one participants provided outcome data. After the intervention, the ability to contract the pelvic floor muscles was acquired by 36% of the experimental group and 12% of the control. The experimental group also improved by a mean of 2 points more than the control group on the ICIQ-UI-SF score. Authors concluded that in women who are unable to contract their pelvic floor muscles voluntarily, 8 weeks of intravaginal electrical stimulation with voluntary contraction attempts improved their ability to contract their pelvic floor muscles and reduced the overall severity and impact of urinary incontinence on quality of life. Although the main estimates of these effects indicate that the effects are large enough to be worthwhile, the precision of these estimates was low, so it is not possible to confirm whether the effects are trivial or worthwhile.

Zhu et al. (2022) evaluated the efficacy and safety of pelvic floor muscle training (PFMT) combined with biofeedback (BF), electrical stimulation (ES) therapy, or both for postpartum lower urinary tract symptoms (LUTS). Seventeen studies were included. The results of the meta-analysis showed that PFMT plus ES with or without BF was more effective than PFMT alone. Patients receiving PFMT plus ES and BF achieved greater improvement than controls receiving PFMT alone in incontinence quality of life scores, pelvic floor muscle strength, and urodynamic parameters (maximum urethral closure pressure, abdominal leak point pressure, and maximum urinary flow rate), and 1-h urine leakage also decreased. Authors concluded that PFMT plus ES with or without BF exhibited better efficacy and safety for early postpartum LUTS than PFMT alone. Ali et al. (2022) sought to determine the effects of nonsurgical, minimally or noninvasive therapies on urge urinary incontinence (UUI) symptoms and quality of life (QoL) in individuals with neurogenic bladder (NGB). Randomized controlled trials that compared therapies such as intravaginal electrical stimulation (IVES), transcutaneous electrical nerve stimulation (TENS), neuromuscular electrical stimulation (NMES), transcutaneous tibial nerve stimulation (TTNS), pelvic floor muscle training (PFMT), and behavioural therapy (BT) to control were included. Meta-analyses revealed a significant effect of electrical stimulation on UUI due to multiple sclerosis and stroke. The pooled analyses of TTNS and revealed significant effects of these interventions on QoL in people with

Parkinson's disease. However, meta-analyses revealed nonsignificant effects for PFMT and BT on UUI due to Parkinson's disease. Authors concluded that their meta-analyses found electrical stimulation to be beneficial for improving the symptoms of UUI among people with multiple sclerosis and those with stroke. The review also revealed that TTNS and BT might improve QoL for people with NGB due to Parkinson's disease, although the effects of PFMT and BT on UUI warrant further investigation.

Sarmiento et al. (2022) perform an updated and comprehensive literature review focused on the effects of pelvic floor electrical stimulation. Regarding the studied populations, the results demonstrated heterogeneity between human and animal populations. Articles comprised studies that investigated the therapeutic effects of electrical stimulation on pelvic floor dysfunctions in humans, totaling 1303 participants. From these, only the research performed by 25 included men in the study population, which investigated 96 patients with urinary incontinence post-radical prostatectomy. Authors concluded that non-invasive electrical stimulation has shown promise in the clinical improvement of disorders associated with pelvic floor fragility. The vast majority of studies addressed in this review showed that electrostimulation improves urination control and sexual quality, in addition to providing greater collagen production and maintaining the effectiveness of sphincter contraction.

Learnardo et al. (2022) compared biofeedback-assisted pelvic muscle floor training (PFMT) and pelvic electrical stimulation (ES) as an intervention group, with PFMT or bladder training (BT) as the control group, in women with an overactive bladder (OAB) in a meta-analysis. Eight studies involving 562 patients (comprising 204 patients with biofeedback-assisted PFMT, 108 patients with pelvic ES, and 250 patients who received PFMT alone or BT and lifestyle recommendations only, as the control group) were included. The ES group showed significant differences in terms of changes to QoL, episodes of incontinence, and the number of participants cured or improved, while the biofeedback group resulted in nonsignificant changes in QoL, episodes of incontinence, and the number of participants cured or improved, both compared to the control group respectively. Authors concluded that this meta-analysis shows that low-frequency pelvic ES appears to be sufficient and effective as an additional intervention for women with OAB in clinical practice according to improvements in the subjects' QoL and reduction of symptoms. Meanwhile, biofeedback-assisted PFMT does not appear to be a significant adjuvant for conservative OAB therapy.

Todhunter-Brown et al. (2022) summarized Cochrane Reviews that assessed the effects of conservative interventions for treating urinary incontinence (UI) in women. The common types of UI are stress (SUI), urgency (UUI) and mixed (MUI). A wide range of interventions can be delivered to reduce the symptoms of UI in women. Conservative interventions are generally recommended as the first line of treatment. Authors included reviews that compared a conservative intervention with 'control' (which included placebo, no treatment or usual care), another conservative intervention or another active, but non-conservative, intervention. They included 29 relevant Cochrane Reviews. Seven focused on physical therapies; five on education, behavioural and lifestyle advice; one on mechanical devices; one on acupuncture and one on yoga. Fourteen focused on non-conservative interventions but had a comparison with a conservative intervention. There were 112 unique trials (including 8975 women) that had primary outcome data included in at least one analysis. For UUI, (five reviews): Conservative intervention versus control: there was moderate to high-certainty evidence demonstrating that PFMT plus feedback, PFMT plus biofeedback, electrical stimulation and bladder training were more beneficial than control for curing or improving UI. Women using electrical stimulation plus PFMT had higher quality of life than women in the control group. One conservative intervention versus another conservative intervention: for cure or improvement, there was moderate certainty evidence that electrical stimulation was more effective than laseropuncture. There was high or moderate certainty evidence that PFMT resulted in higher quality of life than electrical stimulation and electrical stimulation plus PFMT resulted in better cure or improvement and higher quality of life than PFMT alone. For all types of urinary incontinence (13 reviews): Conservative intervention versus control: there was moderate to high certainty evidence of better cure or improvement with PFMT, electrical stimulation, weight loss and cones compared to control. Specific to electrical stimulation and exercise, authors concluded that there is high certainty that PFMT is more beneficial than control for all types of UI for outcomes of cure or improvement and quality of life and electrical stimulation is beneficial for women with UUI. Most evidence within the included Cochrane Reviews is of low certainty.

Stania et al. (2022) sought to determine the therapeutic efficacy of intravaginal electrical stimulation (ES) in women with SUI. Of the 686 records identified, a total of 10 articles met the inclusion criteria. A meta-analysis revealed significant differences between the ES and no active treatment groups in the pooled objective cure rates and subjective cure or improvement rates. No significant differences were found in the pooled number of incontinence episodes per 24 h, the pooled Incontinence Quality of Life Questionnaire scores or the pooled

number of adverse effects between the ES and other conservative treatment groups. Authors concluded that there was insufficient evidence for or against the use of intravaginal ES therapy for women with SUI, partly due to the variability in the interventions of the included trials and the small number of trials included.

### **Cranial Electrotherapy Stimulation**

O'Connell et al. (2018) evaluated the efficacy of non-invasive cortical stimulation techniques in the treatment of chronic pain. Non-invasive brain stimulation techniques aim to induce an electrical stimulation of the brain in an attempt to reduce chronic pain by directly altering brain activity. They include repetitive transcranial magnetic stimulation (rTMS), cranial electrotherapy stimulation (CES), transcranial direct current stimulation (tDCS), transcranial random noise stimulation (tRNS) and reduced impedance non-invasive cortical electrostimulation (RINCE). Outcomes of interest were pain intensity measured using visual analogue scales or numerical rating scales, disability, quality of life and adverse events. A total of 94 trials were included in this review (involving 2983 randomised participants). Authors concluded that there is very low-quality evidence that single doses of high-frequency rTMS of the motor cortex and tDCS may have short-term effects on chronic pain and quality of life but multiple sources of bias exist that may have influenced the observed effects. They did not find evidence that low-frequency rTMS, rTMS applied to the dorsolateral prefrontal cortex and CES are effective for reducing pain intensity in chronic pain. There remains a need for substantially larger, rigorously designed studies. Gatzinsky et al. (2020) surveyed the literature regarding the efficacy and safety of primary motor cortex (M1) rTMS, and the accuracy to predict a positive response to epidural motor cortex stimulation (MCS) which is supposed to give a more longstanding pain relief for chronic neuropathic pain (NP). Data on 5-20 Hz (high-frequency) rTMS vs. sham was extracted from 24 blinded randomised controlled trials which were of varying quality, investigated highly heterogeneous pain conditions, and used excessively variable stimulation parameters. The difference in pain relief between active and sham stimulation was statistically significant in 9 of 11 studies using single-session rTMS, and in 9 of 13 studies using multiple sessions. Baseline data could be extracted from 6 single and 12 multiple session trials with a weighted mean pain reduction induced by active rTMS, compared to baseline, of -19% for single sessions, -32% for multiple sessions with follow-up <30 days, and -24% for multiple sessions with follow-up ≥30 days after the last stimulation session. For single sessions the weighted mean difference in pain reduction between active rTMS and sham was 15 percentage points, for multiple sessions the difference was 22 percentage points for follow-ups <30 days, and 15 percentage points for follow-ups ≥30 days. Authors concluded that rTMS targeting M1 can result in significant reduction of chronic NP which, however, is transient and shows a great heterogeneity between studies; very low certainty of evidence for single sessions and low for multiple sessions. Multiple sessions of rTMS can maintain a more longstanding effect. rTMS seems to be a fairly good predictor of a positive response to epidural MCS and may be used to select patients for implantation of permanent epidural electrodes. More studies are needed to manifest the use of rTMS for this purpose. Pain relief outcomes in a longer perspective, and outcome variables other than pain reduction need to be addressed more consistently in future studies to consolidate the applicability of rTMS in routine clinical practice.

Lloyd et al. (2020) systematically reviewed the most up-to-date literature and perform a meta-analysis of the effects of tDCS on pain intensity in fibromyalgia. Meta-analysis was conducted on studies investigating pain intensity after tDCS in participants with fibromyalgia and analyzed using standardized mean difference and 95% confidence intervals. Fourteen clinical studies were included. Ten were controlled trials and 4 were within-subjects crossover studies. Meta-analysis of data from 8 controlled trials provides tentative evidence of pain reduction when active tDCS is delivered compared to sham. However, substantial statistical heterogeneity and high risk of bias of primary studies prevent more conclusive recommendations being made. Authors concluded that tDCS is a safe intervention with the potential to lower pain intensity in fibromyalgia. However, there is a need for more empirical research of the neural target sites and optimum stimulation parameters to achieve the greatest effects before conducting further clinical studies. Alwardat et al. (2020) evaluated the effectiveness of tDCS on pain reduction and related disability in patients with non-specific chronic low back pain (CLBP). Nine RCTs (411 participants) were included in the systematic review according to inclusion criteria, while only five studies could be included in the meta-analysis. The primary motor cortex (M1) was the main stimulated target. The meta-analysis showed non-significant effect of multiple sessions of tDCS over M1 on pain reduction and disability post-treatment respectively. No significant adverse events were reported. The current results do not support the clinical use of tDCS for the reduction of pain and related disability in non-specific CLBP. However, the limited number of available evidence limits our conclusions on the effectiveness of these approaches.

Szymoniuk et al. (2023) aimed to give an up-to-date overview of brain stimulation methods, including transcranial direct current stimulation (tDCS), repetitive transcranial magnetic stimulation (rTMS), cranial

electrotherapy stimulation (CES), and reduced impedance non-invasive cortical electrostimulation (RINCE) as a potential treatment for chronic pain in a narrative review. According to authors, the majority of studies on the use of brain stimulation in chronic pain are of poor methodology with small sample sizes. Because tDCS and rTMS demonstrated successful results on chronic pain relief with a low rate of side effects, their clinical use is the most beneficial among discussed techniques. Additionally, research on adverse effects is continued to further increase the safety of these methods. Regarding CES and RINCE, further high quality research is needed to confirm findings. There are only a few studies that suggest CES therapy to be beneficial and most clinical trials showed no benefit. RINCE was proven effective in managing chronic pain, but data referred only to one study, so there was the risk of bias due to the small sample size. In summary, rTMS and tDCS represent the most promising therapeutic options for chronic pain among discussed brain stimulation methods. However, due to the low quality of evidence provided by available studies, large multi-center RCTs with long-term follow-ups are necessary to verify the safety and clinical outcomes of non-invasive as well as invasive brain stimulation.

#### **Neufit Neubie device**

There is a paucity of published literature to support the use of the Neufit Neubie device for electrical stimulation and therefore conclusions about the safety and efficacy of the device of combination units cannot be made.

#### **RST-SANEXAS neoGEN® Electric cell-Signaling Treatments (EcST)**

There is no peer reviewed published literature to support the use of the RST-SANEXAS neoGEN® Electric cell-Signaling Treatment (EcST) and therefore conclusions about the safety, and efficacy cannot be made.

#### **Transcutaneous electrical modulation pain reprocessing (TEMPR) (e.g., Scrambler therapy, Calmare®)**

There is insufficient evidence in the published peer reviewed scientific literature to support the efficacy of TEMPR. Studies comparing TEMPR to conventional treatment options and to sham therapy are lacking. Available studies are primarily in the form of case series with small, heterogeneous patient populations and short-term follow-ups investigating TEMPR for the treatment of various types of pain including cancer pain. In some cases, pain relief was not maintained following therapy (Ricci, et al., 2019; Lee, et al., 2016; Notaro, et al., 2016; Coyne, et al., 2013; Ricci, et al., 2011; Smith, et al., 2020; Sabato, et al., 2005; Marineo, et al., 2003).

Marineo et al. (2012) conducted a randomized controlled trial to compare the effects of Scrambler therapy (n=26) to guideline-based drug management (n=26) (control group) for the treatment of pain (i.e., postsurgical neuropathic pain, postherpetic neuralgia or spinal canal stenosis). Scrambler therapy included one 45-minute session a day for ten days at the maximally tolerated stimulus. The primary outcome was change in visual analogue scale (VAS) pain scores at one month. Secondary outcomes included VAS pain scores at two and three months, pain medication usage and allodynia. At the one-month, two-month and three-month follow-up visits, there was a significant reduction in the mean VAS score for the treatment group compared to the control group ( $p < 0.0001$ , each). More relapses occurred in patients with polyradicular pain than monoradicular pain. Relapses in the test group were significant ( $p < 0.001$ ) but not in the control group ( $p > 0.05$ ). No adverse effects were observed. Compared to the control group, allodynia significantly reduced in the Scrambler group at one, two and three months ( $p = 0.0017$ ,  $p = 0.0094$ ,  $p = 0.0644$ , respectively). Scrambler therapy was also associated with significant pain medication reduction and dosage variation was statistically significant ( $p < 0.0001$ ). Author-noted limitations included: lack of a sham comparator, the type of treatment provided to the control group, and the small sample size. Other limitations are the short-term follow-up and heterogeneity of the patient population.

Hou et al. 2018 conducted a systematic review of the literature to assess the safety and efficacy of medical and pharmacological therapies for the treatment of chemotherapy-induced peripheral neuropathy (CIPN). Studies with adult subjects (age  $\geq 18$  years) were included if they were randomized controlled trials (RCTs), prospective non-randomized studies, case-control, cohort, cross-over or retrospective. Case reports, case series, abstracts, review articles, letters to the editor, and animal studies were excluded. In total, 13 RCTs, 18 prospective studies, and four retrospective studies met the inclusion criteria. The studies investigated the use of pharmacotherapy and other numerous modalities including laser therapy, scrambler therapy, magnetic field therapy, dietary therapy, long-wave diathermy therapy, and acupuncture. The primary outcome measures were highly variable across the included studies. The authors' focus was pain relief and change in the severity of CIPN symptoms. Due to the low quality of the studies and the paucity of evidence no recommendation could be made for acupuncture-like transcutaneous nerve stimulation (ALTENS), electro-acupuncture, percutaneous auricular neurostimulation, interferential therapy, low-frequency magnetic field therapy and scrambler therapy. The limitations of this systematic review included: heterogeneity of the studies with variations in timing of treatment,

primary outcomes, and chemotherapeutic agents. Most of the included studies had small sample sizes and short term follow-up periods.

Hayes (2020) evaluated Scrambler/Calmare for the treatment of chronic nonmalignant pain. Nine studies including three randomized controlled trials, one repeated-measure time series (observational studies), three pretest/posttest study and two retrospective reviews were included in the Brief. Outcomes were measured using visual analog scale (VAS), numeric rating scale (NRS), and the Brief Pain Inventory (BPI). No adverse events were reported. Although limited evidence suggested improvement in pain, “substantial uncertainty” remains due to the lack of well-designed comparative studies. The overall quality of the evidence was rated low to very low and Hayes concluded that there was insufficient evidence to assess the impact of Scrambler/Calmare on health outcomes or patient management.

Hayes (2020) also evaluated the literature on Scrambler/Calmare for the management of chronic pain related to cancer or cancer treatment. There was a paucity of “very-low-quality” evidence for cancer-related pain in adult patients. Twelve studies including two randomized controlled trials, nine single arm studies, and one retrospective review meet the inclusion criteria. It is proposed that Scrambler Therapy (ST) may be used as an adjunct to conventional treatments. The long-term durability of relief of pain using ST is unclear. Limitations of the studies included: small patient populations (n=11-83), short term follow-ups, lack of a control group, limited reporting of outcomes, lack of statistical rigor and analyses, lack of blinding, and substantial attrition. There is insufficient evidence to support the safety and effectiveness of Scrambler/Calmare for pain related to cancer and cancer treatment.

Kashyap and Bhatnagar (2020) aimed to detect possible gaps in the literature regarding the efficacy of ST for cancer pain and formulate recommendations for research through a systematic review of the literature. Twenty-seven studies were retrieved. Ten were articles that were categorized as literature reviews, including 7 general literature reviews not following a specific review methodology, 1 editorial, and 2 systematic reviews. Seventeen were original studies, including 2 single-arm trials, 1 randomized controlled trial, 4 pilot trials, 4 case reports, 2 retrospective studies, and 4 prospective studies. By and large, the available literature supports the use of ST as an effective therapy for the management of refractory cancer pain. However, the level of evidence for its application to cancer pain is not particularly strong, and improvement in pain with ST may even be owing to a placebo effect. Authors concluded that methodologically sound, large randomized control trials are needed in this area.

Wang et al. (2022) aimed to summarize the evidence regarding 4 major types of neuromodulation devices for the treatment of painful diabetic neuropathy (PDN). They focused on spinal cord stimulators (SCS), peripheral nerve stimulators (PNS), transcutaneous electrical nerve stimulators (TENS), and scrambler therapy devices (ST) because they are often used for refractory neuropathic pain. Seventeen studies met inclusion criteria, 10 of which were regarding SCS. Only 3 of the 10 were randomized controlled trials. We found no studies assessing contemporary PNS. Four studies assessed TENS, but the devices varied widely in voltages and waveforms. Two case reports described ST. Authors concluded that the evidence for neuromodulation devices for the treatment of PDN mostly comprises open-label prospective trials or case reports. SCS has the most volume of evidence for efficacy. Studies regarding TENS show mixed results, possibly due to numerous device varieties. PNS and ST may hold promise based on their proposed mechanisms of action, but prospective controlled trials are needed.

Jin et al. (2022) aimed to investigate the efficacy of scrambler therapy (ST) for the management of chronic pain in a meta-analysis. Out of 348 studies, a total of 7 RCTs (n = 287 patients) that met the inclusion criteria were included in the final analysis. Overall, ST marginally decreased pain scores after the end of the treatment compared with the control group, with substantial heterogeneity. A subgroup meta-analysis found that the use of ST significantly reduced analgesic consumption compared to the control group. However, no significant efficacy was observed in the subgroup meta-analyses by methodological quality, type of diseases causing pain, and follow-up period. The included trials have a small sample size and low methodological quality. Authors concluded that ST seems to be effective in the management of patients with chronic pain. However, further, large RCTs are warranted to confirm our findings.

---

## Coding Information

**Note:** 1) This list of codes may not be all-inclusive.

2) Deleted codes and codes which are not effective at the time the service is rendered may not be eligible for reimbursement.

**Considered Medically Necessary when criteria in the applicable policy statements listed above are met:**

<b>CPT®*</b> <b>Codes</b>	<b>Description</b>
97014	Application of a modality to 1 or more areas; electrical stimulation (unattended)
97032	Application of a modality to 1 or more areas; electrical stimulation (manual) each 15 minutes

  

<b>HCPCS</b> <b>Codes</b>	<b>Description</b>
G0283	Electrical stimulation unattended, to one or more areas for indication(s) other than wound care, as part of a therapy plan of care

**\*Current Procedural Terminology (CPT®) ©2022 American Medical Association: Chicago, IL.**

---

## References

1. Alamer A, Melese H, Nigussie F. Effectiveness of Neuromuscular Electrical Stimulation on Post-Stroke Dysphagia: A Systematic Review of Randomized Controlled Trials. Clin Interv Aging. 2020 Sep 3;15:1521-1531. doi: 10.2147/CIA.S262596.
2. Ali MU, Fong KN, Kannan P, Bello UM, Kranz G. Effects of nonsurgical, minimally or noninvasive therapies for urinary incontinence due to neurogenic bladder: a systematic review and meta-analysis. Ther Adv Chronic Dis. 2022;13:20406223211063059. Published 2022 Mar 18.
3. Almeida CC, Silva VZMD, Júnior GC, Liebano RE, Durigan JLQ. Transcutaneous electrical nerve stimulation and interferential current demonstrate similar effects in relieving acute and chronic pain: a systematic review with meta-analysis. Braz J Phys Ther. 2018 Sep - Oct;22(5):347-354.
4. Alwardat M, Pisani A, Etoom M, et al. Is transcranial direct current stimulation (tDCS) effective for chronic low back pain? A systematic review and meta-analysis. J Neural Transm (Vienna). 2020;127(9):1257-1270. doi:10.1007/s00702-020-02223-w
5. American Society of Anesthesiologists Task Force on Chronic Pain Management; American Society of Regional Anesthesia and Pain Medicine. Practice Guidelines for Chronic Pain Management: An Updated Report by the American Society of Anesthesiologists Task Force on Chronic Pain Management and the American Society of Regional Anesthesia and Pain Medicine. Anesthesiology 2010; 112(4):810-833.
6. American College of Occupational and Environmental Medicine (ACOEM); 2nd ed. Elk Grove Village (IL); 2007. Low back disorders. Occupational medicine practice guidelines: evaluation and management of common health problems and functional recovery in workers. 366 [1310 references].
7. Aoyagi Y, Tsubahara A. Therapeutic orthosis and electrical stimulation for upper extremity hemiplegia after stroke: a review of effectiveness based on evidence. Top Stroke Rehabil. 2004 Summer;11(3):9-15.
8. Arena R, Pinkstaff S, Wheeler E, Peberdy MA, Guazzi M, Myers J. Neuromuscular electrical stimulation and inspiratory muscle training as potential adjunctive rehabilitation options for patients with heart failure. J Cardiopulm Rehabil Prev. 2010 Jul-Aug;30(4):209-23.

9. Arvidsson I, Arvidsson H, Eriksson E, Jansson E. Prevention of quadriceps wasting after immobilization: An evaluation of the effect of electrical stimulation. *Orthopedics*. 1986;9(11):1519-1528.
10. Barrett C, Taylor P. The effects of the odstock drop foot stimulator on perceived quality of life for people with stroke and multiple sclerosis. *Neuromodulation*. 2010 Jan;13(1):58-64.
11. Bax L, Staes F, Verhagen A. Does neuromuscular electrical stimulation strengthen the quadriceps femoris: A systematic review of randomised controlled trials. *Sports Med*. 2005;35(3):191-212.
12. Beltran-Alacreu H, Serrano-Muñoz D, Martín-Caro D, Fernández-Pérez JJ, Gómez-Soriano J, Avendaño-Coy J. Percutaneous versus transcutaneous electrical nerve stimulation for the treatment of musculoskeletal pain. A systematic review and meta-analysis. *Pain Med*. 2022;23(8):1387-1400. doi:10.1093/pm/pnac027
13. Bergman S. Management of musculoskeletal pain. *Best Pract Res Clin Rheumatol*. 2007;21:153-166.
14. Bethoux F, Rogers HL, Nolan KJ, Abrams GM, Annaswamy T, Brandstater M, Browne B, Burnfield JM, Feng W, Freed MJ, Geis C, Greenberg J, Gudesblatt M, Ikramuddin F, Jayaraman A, Kautz SA, Lutsep HL, Madhavan S, Meilahn J, Pease WS, Rao N, Seetharama S, Sethi P, Turk MA, Wallis RA, Kufta C. Long-Term Follow-up to a Randomized Controlled Trial Comparing Peroneal Nerve Functional Electrical Stimulation to an Ankle Foot Orthosis for Patients With Chronic Stroke. *Neurorehabil Neural Repair*. 2015 Nov-Dec;29(10):911-22.
15. Blum K, Chen AL, Chen TJ, Prihoda TJ, Schoolfield J, DiNubile N, Waite RL, Arcuri V, Kerner M, Braverman ER, Rhoades P, Tung H. The H-Wave device is an effective and safe non-pharmacological analgesic for chronic pain: a meta-analysis. *Adv Ther*. 2008 Jul;25(7):644-57.
16. Blum K, Ho CK, Chen AL, Fulton M, Fulton B, Westcott WL, Reinl G, Braverman ER, Dinubile N, Chen TJ. The H-Wave((R)) Device Induces NO-Dependent Augmented Microcirculation and Angiogenesis, Providing Both Analgesia and Tissue Healing in Sports Injuries. *Phys Sportsmed*. 2008 Dec;36(1):103-14.
17. Bogduk N. Management of chronic low back pain *Med J Aust* 2004; 180 (10): 542-544
18. Bosques G, Martin R, McGee L, Sadowsky C. Does therapeutic electrical stimulation improve function in children with disabilities? A comprehensive literature review. *J Pediatr Rehabil Med*. 2016 May 31;9(2):83-99.
19. Bremner CB, Holcomb WR, Brown CD, Perreault ME. The Effectiveness of Neuromuscular Electrical Stimulation in Improving Voluntary Activation of the Quadriceps: A Critically Appraised Topic. *J Sport Rehabil*. 2016 Nov 11:1-21.
20. Brissot R, Gallien P, Le Bot MP, et al. Clinical experience with functional electrical stimulation-assisted gait with Parastep in spinal cord-injured patients. *Spine*. 2000; 25(4):501-508
21. Calmare®. Retrieved on September 26, 2023 from <http://calmarett.com/>
22. California Technology Assessment Forum. Interferential Stimulation For The Treatment Of Musculoskeletal Pain. 2005. Retrieved on June 15, 2023 from [https://pdfs.semanticscholar.org/bb6f/5e7de69fcaa6cfdbe09dd1511a7447fcbab8.pdf?\\_ga=2.71814416.248400488.1562174960-889652479.1562174960](https://pdfs.semanticscholar.org/bb6f/5e7de69fcaa6cfdbe09dd1511a7447fcbab8.pdf?_ga=2.71814416.248400488.1562174960-889652479.1562174960)

23. Cameron, M. *Physical Agents in Rehabilitation: An Evidence-Based Approach to Practice*. 5th edition. Saunders; 2018.
24. Carnaby-Mann GD, Crary MA. Examining the evidence on neuromuscular electrical stimulation for swallowing: a meta-analysis. *Arch Otolaryngol Head Neck Surg*. 2007 Jun;133(6):564-71.
25. Castel LD, Freburger JK, Holmes GM, Scheinman RP, Jackman AM, Carey TS. Spine and pain clinics serving North Carolina patients with back and neck pain: what do they do, and are they multidisciplinary? *Spine* 2009;34:615-622
26. Cetin N, Aytar A, Atalay A, Akman MN. Comparing hot pack, short-wave diathermy, ultrasound, and TENS on isokinetic strength, pain, and functional status of women with osteoarthritic knees: A single-blind, randomized, controlled trial. *Am J Phys Med Rehabil*. 2008;87:443-451.
27. Chaplin E. Functional neuromuscular stimulation for mobility in people with spinal cord injuries. The Parastep I System. *J Spinal Cord Med* 1996; 19(2):99-105.
28. Chen YW, Chang KH, Chen HC, Liang WM, Wang YH, Lin YN. The effects of surface neuromuscular electrical stimulation on post-stroke dysphagia: a systemic review and meta-analysis. *Clin Rehabil*. 2016 Jan;30(1):24-35.
29. Chen HL, Yang FA, Lee TH, Liou TH, Escorpizo R, Chen HC. Effectiveness of interferential current therapy in patients with knee osteoarthritis: a systematic review and meta-analysis of randomized controlled trials. *Sci Rep*. 2022;12(1):9694. Published 2022 Jun 11. doi:10.1038/s41598-022-13478-6
30. Chen YH, Wang HY, Liao CD, Liou TH, Escorpizo R, Chen HC. Effectiveness of neuromuscular electrical stimulation in improving mobility in children with cerebral palsy: A systematic review and meta-analysis of randomized controlled trials. *Clin Rehabil*. 2023;37(1):3-16. doi:10.1177/02692155221109661
31. Chiu HC, Ada L. Effect of functional electrical stimulation on activity in children with cerebral palsy: a systematic review. *Pediatr Phys Ther*. 2014 Fall;26(3):283-8.
32. Chou R and Hoyt Huffman LH. Nonpharmacologic therapies for acute and chronic low back pain: A review of the evidence for an American Pain Society/American College of Physicians Clinical Practice Guideline. *Annals of Internal Medicine*. 2007;147(7):492-504.
33. Chou R, Qaseem A, Snow V, Casey D, Cross Jr T, Shekelle P, Owens DK. Diagnosis and treatment of low back pain: A joint clinical practice guideline from the American College of Physicians and the American Pain Society. *Annals of Internal Medicine*. 2007;147(7):478-490.
34. Chou R, Deyo R, Friedly J, Skelly A, Hashimoto R, Weimer M, Fu R, Dana T, Kraegel P, Griffin J, Grusing S, Brodt E. Noninvasive Treatments for Low Back Pain. Comparative Effectiveness Review No. 169. (Prepared by the Pacific Northwest Evidence-based Practice Center under Contract No. 290-2012-00014-I.) AHRQ Publication No. 16-EHC004-EF. Rockville, MD: Agency for Healthcare Research and Quality; February 2016.
35. Christiaanse ME, Mabe B, Russell G, Simeone TL, Fortunato J, Rubin B. Neuromuscular electrical stimulation is no more effective than usual care for the treatment of primary dysphagia in children. *Pediatr Pulmonol*. 2011 Jun;46(6):559-65.
36. Clark H, Lazarus C, Arvedson J, Schooling T, Frymark T. Evidence-based systematic review: effects of neuromuscular electrical stimulation on swallowing and neural activation. *Am J Speech Lang Pathol*. 2009 Nov;18(4):361-75.

37. Coyne PJ, Wan W, Dodson P, Swainey C, Smith TJ. A trial of Scrambler therapy in the treatment of cancer pain syndromes and chronic chemotherapy-induced peripheral neuropathy. *J Pain Palliat Care Pharmacother*. 2013 Dec;27(4):359-64.
38. Culvenor AG, Girdwood MA, Juhl CB, et al. Rehabilitation after anterior cruciate ligament and meniscal injuries: a best-evidence synthesis of systematic reviews for the OPTIKNEE consensus. *Br J Sports Med*. 2022;56(24):1445-1453. doi:10.1136/bjsports-2022-105495
39. Dali Cí, Hansen FJ, Pedersen SA, Skov L, Hilden J, Bjørnskov I, Strandberg C, Christensen J, Haugsted U, Herbst G, Lyskjaer U. Threshold electrical stimulation (TES) in ambulant children with CP: a randomized double-blind placebo-controlled clinical trial. *Dev Med Child Neurol*. 2002 Jun;44(6):364-9.
40. Davison P, Wilkinson R, Miller J, Auais M. A systematic review of using electrical stimulation to improve clinical outcomes after hip fractures. *Physiother Theory Pract*. 2022;38(12):1857-1875. doi:10.1080/09593985.2021.1894620
41. Dias LV, Cordeiro MA, Schmidt de Sales R, et al. Immediate analgesic effect of transcutaneous electrical nerve stimulation (TENS) and interferential current (IFC) on chronic low back pain: Randomised placebo-controlled trial. *J Bodyw Mov Ther*. 2021;27:181-190.
42. Dissanayaka TD, Pallegama RW, Suraweera HJ, Johnson MI, Kariyawasam AP. Comparison of the Effectiveness of Transcutaneous Electrical Nerve Stimulation and Interferential Therapy on the Upper Trapezius in Myofascial Pain Syndrome: A Randomized Controlled Study. *Am J Phys Med Rehabil*. 2016 Sep;95(9):663-72.
43. Dubinsky RM, Miyasaki J, American Academy of Neurology, Efficacy of transcutaneous electrical nerve stimulation in the treatment of pain in neurologic disorders (an evidence-based review), *Neurology*® 2010; 74: 173-176.
44. Esnouf JE, Taylor PN, Mann GE, Barrett CL. Impact on activities of daily living using a functional electrical stimulation device to improve dropped foot in people with multiple sclerosis, measured by the Canadian Occupational Performance Measure. *Mult Scler*. 2010 Sep;16(9):1141-7.
45. Evans AG, Horrar AN, Ibrahim MM, et al. Outcomes of transcutaneous nerve stimulation for migraine headaches: a systematic review and meta-analysis. *J Neurol*. 2022;269(8):4021-4029. doi:10.1007/s00415-022-11059-1
46. Everaert DG, Stein RB, Abrams GM, Dromerick AW, Francisco GE, Hafner BJ, Huskey TN, Munin MC, Nolan KJ, Kufra CV. Effect of a foot-drop stimulator and ankle-foot orthosis on walking performance after stroke: a multicenter randomized controlled trial. *Neurorehabil Neural Repair*. 2013 Sep;27(7):579-91.
47. Facci LM, Nowotny JP, Tormem F, Trevisani VF. Effects of transcutaneous electrical nerve stimulation (TENS) and interferential currents (IFC) in patients with nonspecific chronic low back pain: randomized clinical trial. *Sao Paulo Med J*. 2011;129(4):206-16.
48. Fertout A, Manière-Ezvan A, Lupi L, Ehrmann E. Management of temporomandibular disorders with transcutaneous electrical nerve stimulation: A systematic review. *Cranio*. 2022;40(3):217-228. doi:10.1080/08869634.2019.1687986
49. Frequency Specific Microcurrent. Retrieved on June 15, 2023 from <http://frequencyspecific.com/microcurrent-experimental-results-5407/about/>
50. Fuentes JP, Armijo Olivo S, Magee DJ, Gross DP. Effectiveness of interferential current therapy in the management of musculoskeletal pain: a systematic review and meta-analysis. *Phys Ther*. 2010 Sep;90(9):1219-38.

51. Gatzinsky K, Bergh C, Liljegren A, et al. Repetitive transcranial magnetic stimulation of the primary motor cortex in management of chronic neuropathic pain: a systematic review. *Scand J Pain*. 2020;21(1):8-21. Published 2020 Sep 7. doi:10.1515/sjpain-2020-0054
52. Geeganage C, Beavan J, Ellender S, Bath PM. Interventions for dysphagia and nutritional support in acute and subacute stroke. *Cochrane Database Syst Rev*. 2012 Oct 17;10:CD000323.
53. Gatewood CT, Tran AA, Dragoo JL. The efficacy of post-operative devices following knee arthroscopic surgery: a systematic review. *Knee Surg Sports Traumatol Arthrosc*. 2017 Feb;25(2):501-516.
54. Gibson W, Wand BM, Meads C, Catley MJ, O'Connell NE. Transcutaneous electrical nerve stimulation (TENS) for chronic pain - an overview of Cochrane Reviews. *Cochrane Database Syst Rev*. 2019 Apr 3;4(4):CD011890. doi: 10.1002/14651858.CD011890.pub3.
55. Gotlin RS, Hershkowitz S, Juris PM, et al. Electrical stimulation effect on extensor lag and length of hospital stay after total knee arthroplasty. *Arch Phys Med Rehabil*. 1994;75(9):957-959.
56. Graham N, Gross AR, Carlesso LC, Santaguida PL, Macdermid JC, Walton D, Ho E; ICON. An ICON Overview on Physical Modalities for Neck Pain and Associated Disorders. *Open Orthop J*. 2013 Sep 20;7:440-60.
57. Gross AR, Goldsmith C, Hoving JL, Haines T, Peloso P, Aker P, et al. Conservative management of mechanical neck disorders: a systematic review. *J Rheumatol* 2007;34:1083-1102.
58. Gu P, Ran JJ. Electrical Stimulation for Hemiplegic Shoulder Function: A Systematic Review and Meta-Analysis of 15 Randomized Controlled Trials. *Arch Phys Med Rehabil*. 2016 Sep;97(9):1588-94.
59. Guzman J, Haldeman S, Carroll LJ, Carragee EJ, Hurwitz EL, Peloso P, et al. Clinical practice implications of the Bone and Joint Decade 2000-2010 Task Force on Neck Pain and Its Associated Disorders: from concepts and findings to recommendations. *Spine* 2008;33:S199-S213.
60. Hako-Med. Retrieved on June 15, 2023 from <https://hakomed.net/>
61. Haldeman S, Dagenais S. What have we learned about the evidence-informed management of chronic low back pain? *Spine J*. 2008 Jan-Feb;8(1):266-77
62. Hawk C, Whalen W, Farabaugh RJ, Daniels CJ, Minkalis AL, Taylor DN, Anderson D, Anderson K, Crivelli LS, Cark M, Barlow E, Paris D, Sarnat R, Weeks J. Best Practices for Chiropractic Management of Patients with Chronic Musculoskeletal Pain: A Clinical Practice Guideline. *J Altern Complement Med*. 2020 Oct;26(10):884-901. doi: 10.1089/acm.2020.0181.
63. Hayes Inc. Health technology assessment. Scrambler/Calmare pain therapy (Calmare Therapeutics Inc.) for the management of pain not related to cancer. Lansdale, PA: Hayes, Inc. Apr 6, 2020.
64. Hayes Inc. Health technology assessment. Scrambler/Calmare pain therapy (Calmare Therapeutics Inc.) for the management of chronic pain related to cancer or cancer treatment. Lansdale, PA: Hayes, Inc. Mar 30, 2020.
65. Hayes Inc. Hayes Brief. Percutaneous electrical nerve stimulation for treatment of low back pain. Lansdale, PA: Hayes, Inc. Feb 9, 2017.
66. Hou S, Huh B, Kim HK, Kim KH, Abdi S. Treatment of Chemotherapy-Induced Peripheral Neuropathy: Systematic Review and Recommendations. *Pain Physician*. 2018 Nov;21(6):571-592.

67. Houghton PE. Clinical Trials Involving Biphasic Pulsed Current, MicroCurrent, and/or Low-Intensity Direct Current. *Adv Wound Care (New Rochelle)*. 2014 Feb1;3(2):166-183.
68. Howlett OA, Lannin NA, Ada L, McKinstry C. Functional electrical stimulation improves activity after stroke: a systematic review with meta-analysis. *Arch Phys Med Rehabil*. 2015 May;96(5):934-43.
69. Hsueh TC, Cheng PT, Kuan TS, Hong CZ. The immediate effectiveness of electrical nerve stimulation and electrical muscle stimulation on myofascial trigger points. *Am J Phys Med Rehabil* 1997;76:471-476.
70. Huckabee ML, Doeltgen S. Emerging modalities in dysphagia rehabilitation: neuromuscular electrical stimulation. *N Z Med J*. 2007 Oct 12;120(1263):U2744.
71. Hurlow A, Bennett MI, Robb KA, Johnson MI, Simpson KH, Oxberry SG. Transcutaneous electric nerve stimulation (TENS) for cancer pain in adults. *Cochrane Database of Systematic Reviews* 2012, Issue 3. Art. No.: CD006276.
72. Hurwitz EL, Carragee EJ, van d, V, Carroll LJ, Nordin M, Guzman J, et al. Treatment of neck pain: noninvasive interventions: results of the Bone and Joint Decade 2000-2010 Task Force on Neck Pain and Its Associated Disorders. *J Manipulative Physiol Ther* 2009;32:S141-S175.
73. Hussein HM, Alshammari RS, Al-Barak SS, Alshammari ND, Alajlan SN, Althomali OW. A Systematic Review and Meta-analysis Investigating the Pain-Relieving Effect of Interferential Current on Musculoskeletal Pain. *Am J Phys Med Rehabil*. 2022;101(7):624-633. doi:10.1097/PHM.0000000000001870
74. Ignácio Antônio F, Bø K, Pena CC, et al. Intravaginal electrical stimulation increases voluntarily pelvic floor muscle contractions in women who are unable to voluntarily contract their pelvic floor muscles: a randomised trial. *J Physiother*. 2022;68(1):37-42.
75. Iijima H, Takahashi M. Microcurrent Therapy as a Therapeutic Modality for Musculoskeletal Pain: A Systematic Review Accelerating the Translation From Clinical Trials to Patient Care. *Arch Rehabil Res Clin Transl*. 2021;3(3):100145. Published 2021 Jul 21.
76. Imoto AM, Peccin S, Almeida GJ, Saconato H, Atallah ÁN. Effectiveness of electrical stimulation on rehabilitation after ligament and meniscal injuries: a systematic review. *Sao Paulo Med J*. 2011 Dec;129(6):414-23.
77. Jamtvedt G, Dahm KT, Christie A, et al. Physical therapy interventions for patients with osteoarthritis of the knee: An overview of systematic reviews. *Phys Ther*. 2008;88:123-136.
78. Jauregui JJ, Cherian JJ, Gwam CU, Chughtai M, Mistry JB, Elmallah RK, Harwin SF, Bhav A, Mont MA. A Meta-Analysis of Transcutaneous Electrical Nerve Stimulation for Chronic Low Back Pain. *Surg Technol Int*. 2016 Apr;28:296-30.
79. Jin DM, Xu Y, Geng DF, Yan TB. Effect of transcutaneous electrical nerve stimulation on symptomatic diabetic peripheral neuropathy: a meta-analysis of randomized controlled trials. *Diabetes Res Clin Pract*. 2010 Jul;89(1):10-5.
80. Jin Y, Kim D, Hur J, Myung SK. Efficacy of Scrambler Therapy for Management of Chronic Pain: A Meta-Analysis of Randomized Controlled Trials. *Pain Physician*. 2022;25(7):E931-E939.
81. Johnson M, Martinson M. Efficacy of electrical nerve stimulation for chronic musculoskeletal pain: A meta-analysis of randomized controlled trials. *Pain*. 2007;130:157-165.
82. Johnson MI, Paley CA, Howe TE, Sluka KA. Transcutaneous electrical nerve stimulation for acute pain. *Cochrane Database Syst Rev*. 2015 Jun 15;6:CD006142.

83. Johnson MI, Paley CA, Jones G, Mulvey MR, Wittkopf PG. Efficacy and safety of transcutaneous electrical nerve stimulation (TENS) for acute and chronic pain in adults: a systematic review and meta-analysis of 381 studies (the meta-TENS study). *BMJ Open*. 2022;12(2):e051073. Published 2022 Feb 10.
84. Johnston TE, Keller S, Denzer-Weiler C, Brown L. A Clinical Practice Guideline for the Use of Ankle-Foot Orthoses and Functional Electrical Stimulation Post-Stroke. *J Neurol Phys Ther*. 2021;45(2):112-196.
85. Jones S, Man WD, Gao W, Higginson IJ, Wilcock A, Maddocks M. Neuromuscular electrical stimulation for muscle weakness in adults with advanced disease. *Cochrane Database Syst Rev*. 2016 Oct 17;10:CD009419.
86. Kadi MR, Hepgüler S, Atamaz FC, et al. Is interferential current effective in the management of pain, range of motion, and edema following total knee arthroplasty surgery? A randomized double-blind controlled trial. *Clin Rehabil*. 2019; 33(6):1027-1034
87. Kang RW, Lewis PB, Kramer A, Hayden JK, Cole BJ. Prospective randomized single-blinded controlled clinical trial of percutaneous neuromodulation pain therapy device versus sham for the osteoarthritic knee: a pilot study. *Orthopedics*. 2007 Jun;30(6):439-45.
88. Karamian BA, Siegel N, Nourie B, et al. The role of electrical stimulation for rehabilitation and regeneration after spinal cord injury. *J Orthop Traumatol*. 2022;23(1):2. Published 2022 Jan 6.
89. Kashyap K, Bhatnagar S. Evidence for the Efficacy of Scrambler Therapy for Cancer Pain: A Systematic Review. *Pain Physician*. 2020;23(4):349-364.
90. Kerr C, McDowell B, Cosgrove A, Walsh D, Bradbury I, McDonough S. Electrical stimulation in cerebral palsy: a randomized controlled trial. *Dev Med Child Neurol*. 2006 Nov;48(11):870-6.
91. Khadilkar A, Milne S, Brosseau L, Robinson V, Saginur M, Shea B, Tugwell P, Wells G. Transcutaneous electrical nerve stimulation (TENS) for chronic low-back pain. *Cochrane Database Syst Rev*. 2005 Jul 20;(3):CD003008. Review. Update in: *Cochrane Database Syst Rev*. 2008;(4):CD003008.
92. Khadilkar A, Odebiyi DO, Brosseau L, Wells GA. Transcutaneous electrical nerve stimulation (TENS) versus placebo for chronic low-back pain. *Cochrane Database Syst Rev*. 2008 Oct 8;(4):CD003008.
93. Kiger M, Brown CS, Watkins L. Dysphagia management: an analysis of patient outcomes using VitalStim therapy compared to traditional swallow therapy. *Dysphagia*. 2006 Oct;21(4):243-53.
94. Kim KM, Croy T, Hertel J, Saliba S. Effects of neuromuscular electrical stimulation after anterior cruciate ligament reconstruction on quadriceps strength, function, and patient-oriented outcomes: a systematic review. *J Orthop Sports Phys Ther*. 2010 Jul;40(7):383-91.
95. Klose KJ, Jacobs PL, Broton JG, et al. Evaluation of a training program for persons with SCI paraplegia using the Parastep 1 ambulation system: part 1. Ambulation performance and anthropometric measures. *Arch Phys Med Rehabil*. 1997;78(8):789-793. doi:10.1016/s0003-9993(97)90188-x
96. Koyuncu E, Nakipoğlu-Yüzer GF, Doğan A, Ozgirgin N. The effectiveness of functional electrical stimulation for the treatment of shoulder subluxation and shoulder pain in hemiplegic patients: A randomized controlled trial. *Disabil Rehabil*. 2010;32(7):560-6.

97. Kristensen MGH, Busk H, Wienecke T. Neuromuscular Electrical Stimulation Improves Activities of Daily Living Post Stroke: A Systematic Review and Meta-analysis. *Arch Rehabil Res Clin Transl*. 2021;4(1):100167. Published 2021 Nov 12.
98. Labanca L, Bonsanto F, Raffa D, Orlandi Magli A, Grazia Benedetti M. Does adding neuromuscular electrical stimulation to rehabilitation following total knee arthroplasty lead to a better quadriceps muscle strength recovery? A systematic review. *Int J Rehabil Res*. 2022;45(2):118-125. doi:10.1097/MRR.0000000000000525.
99. Lee SC, Park KS, Moon JY, Kim EJ, Kim YC, Seo H, Sung JK, Lee da J. An exploratory study on the effectiveness of "Calmare therapy" in patients with cancer-related neuropathic pain: A pilot study. *Eur J Oncol Nurs*. 2016 Apr;21:1-7.
100. Leonardo K, Seno DH, Mirza H, Afriansyah A. Biofeedback-assisted pelvic floor muscle training and pelvic electrical stimulation in women with overactive bladder: A systematic review and meta-analysis of randomized controlled trials. *Neurourol Urodyn*. 2022;41(6):1258-1269. doi:10.1002/nau.24984
101. Liang Y, Lin J, Wang H, et al. Evaluating the Efficacy of VitalStim Electrical Stimulation Combined with Swallowing Function Training for Treating Dysphagia following an Acute Stroke. *Clinics (Sao Paulo)*. 2021;76:e3069. Published 2021 Nov 8. doi:10.6061/clinics/2021/e3069
102. Lloyd DM, Wittkopf PG, Arendsen LJ, Jones AKP. Is Transcranial Direct Current Stimulation (tDCS) Effective for the Treatment of Pain in Fibromyalgia? A Systematic Review and Meta-Analysis. *J Pain*. 2020;21(11-12):1085-1100. doi:10.1016/j.jpain.2020.01.003
103. Loh MS, Kuan YC, Wu CW, Liao CD, Hong JP, Chen HC. Upper Extremity Contralaterally Controlled Functional Electrical Stimulation Versus Neuromuscular Electrical Stimulation in Post-Stroke Individuals: A Meta-Analysis of Randomized Controlled Trials. *Neurorehabil Neural Repair*. 2022;36(7):472-482. doi:10.1177/15459683221092647
104. Maddocks M, Gao W, Higginson IJ, Wilcock A. Neuromuscular electrical stimulation for muscle weakness in adults with advanced disease. *Cochrane Database Syst Rev*. 2013 Jan 31;1:CD009419.
105. Mahmoudi Z, Mohammadi R, Sadeghi T, Kalbasi G. The Effects of Electrical Stimulation of Lower Extremity Muscles on Balance in Stroke Patients: A Systematic Review of Literatures. *J Stroke Cerebrovasc Dis*. 2021;30(8):105793.
106. Marineo G, Iorno V, Gandini C, Moschini V, Smith TJ. Scrambler therapy may relieve chronic neuropathic pain more effectively than guideline-based drug management: results of a pilot, randomized, controlled trial. *J Pain Symptom Manage*. 2012 Jan;43(1):87-95. doi: 10.1016/j.jpainsymman.2011.03.015.
107. Miller S, Peters K, Ptak M. Review of the effectiveness of neuromuscular electrical stimulation in the treatment of dysphagia - an update. *Ger Med Sci*. 2022;20:Doc08. Published 2022 Jun 14. doi:10.3205/000310
108. Monaghan B, Caulfield B, O'Mathúna DP. Surface neuromuscular electrical stimulation for quadriceps strengthening pre and post total knee replacement. *Cochrane Database Syst Rev*. 2010 Jan 20;(1):CD007177.
109. Morawietz C, Moffat F. Effects of locomotor training after incomplete spinal cord injury: a systematic review. *Arch Phys Med Rehabil*. 2013;94(11):2297-2308. doi:10.1016/j.apmr.2013.06.023

110. Mulvey MR, Bagnall AM, Johnson MI, Marchant PR. Transcutaneous electrical nerve stimulation (TENS) for phantom pain and stump pain following amputation in adults. *Cochrane Database of Systematic Reviews* 2010, Issue 5. Art. No.: CD007264.
111. Nair HKR. Microcurrent as an adjunct therapy to accelerate chronic wound healing and reduce patient pain. *J Wound Care*. 2018 May 2;27(5):296-306.
112. Nnoaham KE, Kumbang J. Transcutaneous electrical nerve stimulation (TENS) for chronic pain. *Cochrane Database Syst Rev*. 2008:CD003222.
113. National Guideline Centre (UK). Evidence review for electrical physical modalities for chronic primary pain: Chronic pain (primary and secondary) in over 16s: assessment of all chronic pain and management of chronic primary pain. London: National Institute for Health and Care Excellence (NICE); April 2021.
114. Nooijen CF, Ter Hoeve N, Field-Fote EC. Gait quality is improved by locomotor training in individuals with SCI regardless of training approach. *J Neuroeng Rehabil*.
115. Notaro P, Dell'Agnola CA, Dell'Agnola AJ, Amatu A, Bencardino KB, Siena S. Pilot evaluation of scrambler therapy for pain induced by bone and visceral metastases and refractory to standard therapies. *Support Care Cancer*. 2016 Apr;24(4):1649-54.
116. Novak S, Gueron G, Zou Z, Cheung G, Berteau JP. New Guidelines for Electrical Stimulation Parameters in Adult Patients With Knee Osteoarthritis Based on a Systematic Review of the Current Literature. *Am J Phys Med Rehabil*. 2020 Aug;99(8):682-688. doi: 10.1097/PHM.0000000000001409.
117. O'Connell NE, Marston L, Spencer S, DeSouza LH, Wand BM. Non-invasive brain stimulation techniques for chronic pain. *Cochrane Database Syst Rev*. 2018 Mar 16;3:CD008208.
118. Ottawa panel evidence-based clinical practice guidelines for electrotherapy and thermotherapy interventions in the management of rheumatoid arthritis in adults. *Phys Ther*. 2004;84:1016-1043.
119. Ou CH, Shiue CC, Kuan YC, Liou TH, Chen HC, Kuo TJ. Neuromuscular Electrical Stimulation of Upper Limbs in Patients With Cerebral Palsy: A Systematic Review and Meta-analysis of Randomized Controlled Trials. *Am J Phys Med Rehabil*. 2023;102(2):151-158. doi:10.1097/PHM.0000000000002058
120. Paley CA, Wittkopf PG, Jones G, Johnson MI. Does TENS Reduce the Intensity of Acute and Chronic Pain? A Comprehensive Appraisal of the Characteristics and Outcomes of 169 Reviews and 49 Meta-Analyses. *Medicina (Kaunas)*. 2021;57(10):1060. Published 2021 Oct 4. doi:10.3390/medicina57101060
121. Page MJ, Green S, Mrocki MA, Surace SJ, Deitch J, McBain B, Lyttle N, Buchbinder R. Electrotherapy modalities for rotator cuff disease. *Cochrane Database Syst Rev*. 2016 Jun 10;(6):CD012225.
122. Pan H, Bao Y, Cao H, Jin R, Wang P, Zhang J. The effectiveness of magnetic stimulation for patients with pelvic floor dysfunction: A systematic review and meta-analysis. *Neurourol Urodyn*. 2018 Nov;37(8):2368-2381
123. Peng L, Wang K, Zeng Y, Wu Y, Si H, Shen B. Effect of Neuromuscular Electrical Stimulation After Total Knee Arthroplasty: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. *Front Med (Lausanne)*. 2021;8:779019. Published 2021 Dec 3.
124. Pereira S, Mehta S, McIntyre A, Lobo L, Teasell RW. Functional electrical stimulation for improving gait in persons with chronic stroke. *Top Stroke Rehabil*. 2012 Nov-Dec;19(6):491-8.

125. Philadelphia panel evidence-based clinical practice guidelines on selected rehabilitation interventions for knee pain. *Phys Ther.* 2001;81:1675-1700.
126. Philadelphia panel evidence-based clinical practice guidelines on selected rehabilitation interventions for shoulder pain. *Phys Ther.* 2001;81:1719-1730.
127. Philadelphia Panel. Philadelphia Panel evidence-based clinical practice guidelines on selected rehabilitation interventions for low back pain. *Phys Ther.* 2001;81(10):1641-74.
128. Pieber K, Herceg M, Paternostro-Sluga T. Electrotherapy for the treatment of painful diabetic peripheral neuropathy: a review. *J Rehabil Med.* 2010 Apr;42(4):289-95.
129. Pietrosimone B, Luc-Harkey BA, Harkey MS, Davis-Wilson HC, Pfeiffer SJ, Schwartz TA, Nissman D, Padua DA, Blackburn JT, Spang JT. Using TENS to Enhance Therapeutic Exercise in Individuals with Knee Osteoarthritis. *Med Sci Sports Exerc.* 2020 Oct;52(10):2086-2095. doi: 10.1249/MSS.0000000000002353.
130. Pivec R, Stokes M, Chitnis AS, Paulino CB, Harwin SF, Mont MA. Clinical and economic impact of TENS in patients with chronic low back pain: analysis of a nationwide database. *Orthopedics.* 2013 Dec;36(12):922-8.
131. Plaza-Manzano G, Gómez-Chigüano GF, Cleland JA, Arias-Buría JL, Fernández-de-Las-Peñas C, Navarro-Santana MJ. Effectiveness of percutaneous electrical nerve stimulation for musculoskeletal pain: A systematic review and meta-analysis. *Eur J Pain.* 2020 Jul;24(6):1023-1044. doi: 10.1002/ejp.1559.
132. Poitras S, Brosseau L. Evidence-informed management of chronic low back pain with transcutaneous electrical nerve stimulation, interferential current, electrical muscle stimulation, ultrasound, and thermotherapy. *Spine J.* 2008 Jan-Feb;8(1):226-33.
133. Postans NJ, Hasler JP, Granat MH, Maxwell DJ. Functional electric stimulation to augment partial weight-bearing supported treadmill training for patients with acute incomplete spinal cord injury: A pilot study. *Arch Phys Med Rehabil.* 2004 Apr;85(4):604-10.
134. Pomeroy VM, King L, Pollock A, Baily-Hallam A, Langhorne P. Electrostimulation for promoting recovery of movement or functional ability after stroke. *Cochrane Database Syst Rev.* 2006 Apr 19;(2):CD003241.
135. Prenton S, Hollands KL, Kenney LP. Functional electrical stimulation versus ankle foot orthoses for foot-drop: A meta-analysis of orthotic effects. *J Rehabil Med.* 2016 Oct 5;48(8):646-656.
136. Price CI, Pandyan AD. Electrical stimulation for preventing and treating post-stroke shoulder pain. *Cochrane Database Syst Rev.* 2000;(4):CD001698.
137. Propp R, Gill PJ, Marcus S, et al. Neuromuscular electrical stimulation for children with dysphagia: a systematic review. *BMJ Open.* 2022;12(3):e055124. Published 2022 Mar 25. doi:10.1136/bmjopen-2021-055124
138. Qaseem A, Wilt TJ, McLean RM, Forciea MA; Clinical Guidelines Committee of the American College of Physicians.. Noninvasive Treatments for Acute, Subacute, and Chronic Low Back Pain: A Clinical Practice Guideline From the American College of Physicians. *Ann Intern Med.* 2017 Apr 4;166(7):514-530.
139. Rampazo ÉP, Martignago CCS, de Noronha M, Liebano RE. Transcutaneous electrical stimulation in neck pain: A systematic review and meta-analysis. *Eur J Pain.* 2022;26(1):18-42.

140. Rampazo ÉP, Liebano RE. Analgesic Effects of Interferential Current Therapy: A Narrative Review. *Medicina (Kaunas)*. 2022;58(1):141. Published 2022 Jan 17. doi:10.3390/medicina58010141
141. Reichenbach S, Jüni P, Hincapié CA, et al. Effect of transcutaneous electrical nerve stimulation (TENS) on knee pain and physical function in patients with symptomatic knee osteoarthritis: the ETRELKA randomized clinical trial. *Osteoarthritis Cartilage*. 2022;30(3):426-435.
142. Robb K, Oxberry SG, Bennett MI, Johnson MI, Simpson KH, Searle RD. A cochrane systematic review of transcutaneous electrical nerve stimulation for cancer pain. *J Pain Symptom Manage*. 2009 Apr;37(4):746-53.
143. Rajpurohit B, Khatri SM, Metgud D, Bagewadi A. Effectiveness of transcutaneous electrical nerve stimulation and microcurrent electrical nerve stimulation in bruxism associated with masticatory muscle pain--a comparative study. *Indian J Dent Res*. 2010 Jan-Mar;21(1):104-6.
144. Ricci M, Fabbri L, Pirotti S, Ruffilli N, Foca F, Maltoni M. Scrambler therapy: what's new after 15 years? The results from 219 patients treated for chronic pain. *Medicine (Baltimore)*. 2019 Jan;98(2):e13895.
145. Ricci M, Pirotti S, Scarpi E, Burgio M, Maltoni M, Sansoni E, Amadori D. Managing chronic pain: results from an open-label study using MC5-A Calmare® device. *Support Care Cancer*. 2012 Feb;20(2):405-12. Epub 2011 Mar 11.
146. RST-SANEXAS neoGEN® Electric cell-Signaling Treatments (EcST). Retrieved on June 15, 2023 from <https://www.rstsanexas.com/neogen/>
147. Rutjes AW, Nüesch E, Sterchi R, Kalichman L, Hendriks E, Osiri M, Brosseau L, Reichenbach S, Jüni P. Transcutaneous electrostimulation for osteoarthritis of the knee. *Cochrane Database Syst Rev*. 2009 Oct 7;(4):CD002823.
148. Sabato AF, Marineo G, Gatti A. Scrambler therapy. *Minerva Anesthesiol*. 2005 Jul-Aug;71(7-8):479-82.
149. Shariffar S, Shuster JJ, Bishop MD. Adding electrical stimulation during standard rehabilitation after stroke to improve motor function. A systematic review and meta-analysis. *Ann Phys Rehabil Med*. 2018;61(5):339-344.
150. Sillen MJ, Speksnijder CM, Eterman RM, Janssen PP, Wagers SS, Wouters EF, Uszko-Lencer NH, Spruit MA. Effects of neuromuscular electrical stimulation of muscles of ambulation in patients with chronic heart failure or COPD: a systematic review of the English-language literature. *Chest*. 2009 Jul;136(1):44-61.
151. Sluka KA, Walsh D. Transcutaneous electrical nerve stimulation: Basic science mechanisms and clinical effectiveness. *J Pain*. 2003;4:109-121.
152. Shaw GY, Sechtem PR, Searl J, Keller K, Rawi TA, Dowdy E. Transcutaneous neuromuscular electrical stimulation (VitalStim) curative therapy for severe dysphagia: myth or reality? *Ann Otol Rhinol Laryngol*. 2007 Jan;116(1):36-44.
153. Sluka KA, Bjordal JM, Marchand S, Rakel BA. What makes transcutaneous electrical nerve stimulation work? Making sense of the mixed results in the clinical literature. *Phys. Ther*. 2013;93(10):1397–1402.
154. Smith TJ, Razzak AR, Blackford AL, et al. A pilot randomized sham-controlled trial of mc5-a scrambler therapy in the treatment of chronic chemotherapy-induced peripheral neuropathy (CIPN). *J Palliat Care*. 2020;35(1):53-58.

155. Snyder-Mackler L, Ladin Z, Schepsis AA, Young JC. Electrical stimulation of the thigh muscles after reconstruction of the anterior cruciate ligament. *J Bone Joint Surg.* 1991;73(7):1025-1036.
156. Snyder-Mackler L, Delitto A, Bailey SL, Stralka SW. Strength of the quadriceps femoris muscle and functional recovery after reconstruction of the anterior cruciate ligament. A prospective, randomized clinical trial of electrical stimulation. *J Bone Joint Surg Am.* 1995;77(8):1166-1173.
157. Springer S, Khamis S. Effects of functional electrical stimulation on gait in people with multiple sclerosis - A systematic review. *Mult Scler Relat Disord.* 2017 Apr;13:4-12.
158. Stania M, Niemiec B, Kamieniarz A, Chmielewska D. Intravaginal electrical stimulation as a monotherapy for female stress urinary incontinence: A systematic review and meta-analysis. *Complement Ther Clin Pract.* 2022;49:101624. doi:10.1016/j.ctcp.2022.101624
159. Stein RB, Everaert DG, Thompson AK, Chong SL, Whittaker M, Robertson J, Kuether G. Long-term therapeutic and orthotic effects of a foot drop stimulator on walking performance in progressive and nonprogressive neurological disorders. *Neurorehabil Neural Repair.* 2010 Feb;24(2):152-67
160. Stein C, Fritsch CG, Robinson C, Sbruzzi G, Plentz RD. Effects of electrical stimulation in spastic muscles after stroke: systematic review and meta-analysis of randomized controlled trials. *Stroke.* 2015 Aug;46(8):2197-205.
161. Stewart F, Berghmans B, Bø K, Glazener CM. Electrical stimulation with non-implanted devices for stress urinary incontinence in women. *Cochrane Database Syst Rev.* 2017 Dec 22;12:CD012390.
162. Szymoniuk M, Chin JH, Domagalski Ł, Biszewski M, Jóźwik K, Kamieniak P. Brain stimulation for chronic pain management: a narrative review of analgesic mechanisms and clinical evidence. *Neurosurg Rev.* 2023;46(1):127. Published 2023 May 29. doi:10.1007/s10143-023-02032-1
163. Tan C, Liu Y, Li W, Liu J, Chen L. Transcutaneous neuromuscular electrical stimulation can improve swallowing function in patients with dysphagia caused by non-stroke diseases: a meta-analysis. *J Oral Rehabil.* 2013 Jun;40(6):472-80.
164. Teoli D, An J. Transcutaneous Electrical Nerve Stimulation. In: *StatPearls. Treasure Island (FL): StatPearls Publishing; November 4, 2021.*
165. Terré R, Mearin F. A randomized controlled study of neuromuscular electrical stimulation in oropharyngeal dysphagia secondary to acquired brain injury. *Eur J Neurol.* 2015 Apr;22(4):687-e44.
166. Todhunter-Brown A, Hazelton C, Campbell P, Elders A, Hagen S, McClurg D. Conservative interventions for treating urinary incontinence in women: an Overview of Cochrane systematic reviews. *Cochrane Database Syst Rev.* 2022;9(9):CD012337. Published 2022 Sep 2. doi:10.1002/14651858.CD012337.pub2
167. van der Scheer JW, Goosey-Tolfrey VL, Valentino SE, Davis GM, Ho CH. Functional electrical stimulation cycling exercise after spinal cord injury: a systematic review of health and fitness-related outcomes. *J Neuroeng Rehabil.* 2021;18(1):99. Published 2021 Jun 12.
168. Van Peppen RP, Kwakkel G, Wood-Dauphinee S, Hendriks HJ, Van der Wees PJ, Dekker J. The impact of physical therapy on functional outcomes after stroke: what's the evidence? *Clin Rehabil.* 2004 Dec;18(8):833-62.
169. Vance CG, Dailey DL, Rakel BA, Sluka KA. Using TENS for pain control: the state of the evidence. *Pain Manag.* 2014 May;4(3):197-209.
170. Vance CGT, Dailey DL, Chimenti RL, Van Gorp BJ, Crofford LJ, Sluka KA. Using TENS for Pain Control: Update on the State of the Evidence. *Medicina (Kaunas).* 2022;58(10):1332. Published 2022 Sep 22. doi:10.3390/medicina58101332

171. Walsh DM. TENS: Clinical Applications and Related Theory. In. New York: Churchill Livingstone; 1997.
172. Walsh NE, Brooks P, Hazes JM, et al. Standards of care for acute and chronic musculoskeletal pain: The bone and joint decade (2000-2010). *Arch Phys Med Rehabil.* 2008;89:1830-1845.
173. Wang EJ, Berninger LE, Komargodski O, Smith TJ. Painful Diabetic Neuropathy - Spinal Cord Stimulation, Peripheral Nerve Stimulation, Transcutaneous Electrical Nerve Stimulation, and Scrambler Therapy: A Narrative Review. *Pain Physician.* 2022;25(8):E1163-E1173.
174. Weiner DK, Perera S, Rudy TE, Glick RM, Shenoy S, Delitto A. Efficacy of percutaneous electrical nerve stimulation and therapeutic exercise for older adults with chronic low back pain: a randomized controlled trial. *Pain.* 2008 Nov 30;140(2):344-57.
175. Welch V., Brosseau L, Saginur M, Shea B, Tugwell P, Wells G. Transcutaneous electrical nerve stimulation (TENS) for chronic low back pain. *Cochrane Database Syst Rev.* 2001;(2):CD003008.
176. Williamson TK, Rodriguez HC, Gonzaba A, Poddar N, Norwood SM, Gupta A. H-Wave® Device Stimulation: A Critical Review. *J Pers Med.* 2021;11(11):1134. Published 2021 Nov 2.
177. Wu Y, Zhu F, Chen W, Zhang M. Effects of transcutaneous electrical nerve stimulation (TENS) in people with knee osteoarthritis: A systematic review and meta-analysis. *Clin Rehabil.* 2022;36(4):472-485. doi:10.1177/02692155211065636
178. Yan T, Hui-Chan CW, Li LS. Functional electrical stimulation improves motor recovery of the lower extremity and walking ability of subjects with first acute stroke: a randomized placebo-controlled trial. *Stroke.* 2005 Jan;36(1):80-5.
179. Yan D, Vassar R. Neuromuscular electrical stimulation for motor recovery in pediatric neurological conditions: a scoping review. *Dev Med Child Neurol.* 2021;63(12):1394-1401.
180. Ye G, Grabke EP, Pakosh M, Furlan JC, Masani K. Clinical Benefits and System Design of FES-Rowing Exercise for Rehabilitation of Individuals with Spinal Cord Injury: A Systematic Review. *Arch Phys Med Rehabil.* 2021;102(8):1595-1605.
181. Yue C, Zhang X, Zhu Y, Jia Y, Wang H, Liu Y. Systematic Review of Three Electrical Stimulation Techniques for Rehabilitation After Total Knee Arthroplasty. *J Arthroplasty.* 2018 Jul;33(7):2330-2337.
182. Zeng C, Li H, Yang T, Deng ZH, Yang Y, Zhang Y, Lei GH. Electrical stimulation for pain relief in knee osteoarthritis: systematic review and network meta-analysis. *Osteoarthritis Cartilage.* 2015 Feb;23(2):189-202.
183. Zhu D, Xia Z, Yang Z. Effectiveness of physiotherapy for lower urinary tract symptoms in postpartum women: systematic review and meta-analysis. *Int Urogynecol J.* 2022;33(3):507-521.
184. Zhu Q, Gao G, Wang K, Lin J. Effect of Functional Electrical Stimulation on Gait Parameters in Children with Cerebral Palsy: A Meta-Analysis. *Comput Math Methods Med.* 2022;2022:3972958. Published 2022 Sep 22. doi:10.1155/2022/3972958
185. Zuim PR, Garcia AR, Turcio KH, Hamata MM. Evaluation of microcurrent electrical nerve stimulation (MENS) effectiveness on muscle pain in temporomandibular disorders patients. *J Appl Oral Sci.* 2006 Jan;14(1):61-6.

---

“Cigna Companies” refers to operating subsidiaries of The Cigna Group. All products and services are provided exclusively by or through such operating subsidiaries, including Cigna Health and Life Insurance Company, Connecticut General Life Insurance Company, Evernorth Behavioral Health, Inc., Cigna Health Management, Inc., and HMO or service company subsidiaries of The Cigna Group. © 2023 The Cigna Group.